A	O
novel	O
lncRNA	O
uc	O
.	O
134	O
represses	O
hepatocellular	B-DS
carcinoma	I-DS
progression	O
by	O
inhibiting	O
CUL4A	B-GP
-	O
mediated	O
ubiquitination	O
of	O
LATS1	B-GP

Background	O

Hepatocellular	B-DS
carcinoma	I-DS
(	O
HCC	B-DS
)	O
is	O
one	O
of	O
the	O
most	O
common	O
malignancies	O
worldwide	O
,	O
and	O
tumor	B-DS
recurrence	O
and	O
metastasis	O
are	O
major	O
factors	O
that	O
contribute	O
to	O
the	O
poor	O
outcome	O
of	O
patients	O
with	O
HCC	B-DS
.	O

Long	O
noncoding	O
RNAs	O
(	O
lncRNAs	O
)	O
are	O
known	O
to	O
regulate	O
different	O
tumorigenic	O
processes	O
,	O
and	O
a	O
growing	O
body	O
of	O
evidence	O
indicates	O
that	O
Hippo	B-GP
kinase	I-GP
signaling	O
is	O
inactivated	O
in	O
many	O
cancers	B-DS
.	O

However	O
,	O
the	O
upstream	O
lncRNA	O
regulators	O
of	O
Hippo	B-GP
kinase	I-GP
signaling	O
in	O
HCC	B-DS
are	O
poorly	O
understood	O
.	O

Methods	O

Using	O
a	O
lncRNA	O
microarray	O
,	O
we	O
identified	O
a	O
novel	O
lncRNA	O
,	O
uc	O
.	O
134	O
,	O
whose	O
expression	O
was	O
significantly	O
decreased	O
in	O
the	O
highly	O
aggressive	O
HCC	B-DS
cell	O
line	O
HCCLM3	O
compared	O
with	O
MHCC97L	O
cells	O
.	O

Furthermore	O
,	O
we	O
evaluated	O
uc	O
.	O
134	O
expression	O
in	O
clinical	O
samples	O
using	O
in	O
situ	O
hybridization	O
(	O
ISH	O
)	O
and	O
quantitative	O
real	O
-	O
time	O
polymerase	B-GP
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
analysis	O
.	O

The	O
full	O
-	O
length	O
transcript	O
of	O
uc	O
.	O
134	O
was	O
confirmed	O
using	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
(	O
RACE	O
)	O
analyses	O
.	O

To	O
investigate	O
the	O
biological	O
function	O
of	O
uc	O
.	O
134	O
,	O
we	O
performed	O
gain	O
-	O
of	O
-	O
function	O
and	O
loss	O
-	O
of	O
-	O
function	O
studies	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
underlying	O
mechanisms	O
of	O
uc	O
.	O
134	O
in	O
HCC	B-DS
were	O
investigated	O
using	O
RNA	O
pulldown	O
,	O
RNA	O
immunoprecipitation	O
,	O
ubiquitination	O
assays	O
,	O
Western	O
blotting	O
,	O
mRNA	O
microarray	O
analyses	O
,	O
and	O
qRT	O
-	O
PCR	O
analyses	O
.	O

Results	O

The	O
ISH	O
assay	O
revealed	O
that	O
uc	O
.	O
134	O
expression	O
was	O
significantly	O
decreased	O
in	O
170	O
paraffin	O
-	O
embedded	O
samples	O
from	O
patients	O
with	O
HCC	B-DS
compared	O
with	O
adjacent	O
tissues	O
and	O
uc	O
.	O
134	O
expression	O
directly	O
correlated	O
with	O
patient	O
prognosis	O
.	O

Furthermore	O
,	O
we	O
defined	O
a	O
1867	O
-	O
bp	O
full	O
-	O
length	O
transcript	O
of	O
uc	O
.	O
134	O
using	O
5	O
′-	O
and	O
3	O
′-	O
RACE	O
analysis	O
.	O

The	O
overexpression	O
of	O
uc	O
.	O
134	O
inhibited	O
HCC	B-DS
cell	O
proliferation	O
,	O
invasion	O
,	O
and	O
metastasis	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
whereas	O
the	O
knockdown	O
of	O
uc	O
.	O
134	O
produced	O
the	O
opposite	O
results	O
.	O

Furthermore	O
,	O
we	O
confirmed	O
that	O
uc	O
.	O
134	O
(	O
1408	O
–	O
1867	O
nt	O
)	O
binds	O
to	O
CUL4A	B-GP
(	O
592	O
–	O
759	O
aa	O
region	O
)	O
and	O
inhibits	O
its	O
nuclear	O
export	O
.	O

Moreover	O
,	O
we	O
demonstrated	O
that	O
uc	O
.	O
134	O
inhibits	O
the	O
CUL4A	B-GP
-	O
mediated	O
ubiquitination	O
of	O
LATS1	B-GP
and	O
increases	O
YAPS127	O
phosphorylation	O
to	O
silence	O
the	O
target	O
genes	O
of	O
YAP	B-GP
.	O

Finally	O
,	O
a	O
positive	O
correlation	O
between	O
uc	O
.	O
134	O
,	O
LATS1	B-GP
,	O
and	O
pYAPS127	O
was	O
confirmed	O
in	O
90	O
paraffin	O
-	O
embedded	O
samples	O
by	O
ISH	O
and	O
immunohistochemical	O
staining	O
.	O

Conclusions	O

Our	O
study	O
identifies	O
that	O
a	O
novel	O
lncRNA	O
,	O
uc	O
.	O
134	O
,	O
represses	O
hepatocellular	B-DS
carcinoma	I-DS
progression	O
by	O
inhibiting	O
the	O
CUL4A	B-GP
-	O
mediated	O
ubiquitination	O
of	O
LATS1	B-GP
and	O
increasing	O
YAPS127	O
phosphorylation	O
.	O

The	O
use	O
of	O
this	O
lncRNA	O
may	O
offer	O
a	O
promising	O
treatment	O
approach	O
by	O
inhibiting	O
YAP	B-GP
and	O
activating	O
Hippo	B-GP
kinase	I-GP
signaling	O
.	O

Electronic	O
supplementary	O
material	O

The	O
online	O
version	O
of	O
this	O
article	O
(	O
doi	O
:	O
10	O
.	O
1186	O
/	O
s13045	O
-	O
017	O
-	O
0449	O
-	O
4	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

Background	O

Hepatocellular	B-DS
carcinoma	I-DS
(	O
HCC	B-DS
)	O
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
cancer	B-DS
mortality	O
worldwide	O
[	O
1	O
,	O
2	O
].	O

Currently	O
,	O
surgical	O
treatment	O
for	O
HCC	B-DS
is	O
only	O
available	O
in	O
the	O
initial	O
stage	O
of	O
the	O
disease	O
,	O
but	O
most	O
patients	O
present	O
with	O
advanced	O
disease	O
upon	O
diagnosis	O
,	O
at	O
which	O
point	O
the	O
efficacy	O
of	O
radiotherapy	O
and	O
chemotherapy	O
is	O
limited	O
.	O

The	O
high	O
rate	O
of	O
tumor	B-DS
recurrence	O
and	O
metastasis	O
are	O
major	O
factors	O
that	O
contribute	O
to	O
the	O
poor	O
prognosis	O
of	O
patients	O
with	O
HCC	B-DS
.	O

Therefore	O
,	O
novel	O
insights	O
into	O
the	O
mechanism	O
of	O
HCC	B-DS
are	O
urgently	O
needed	O
to	O
identify	O
novel	O
prognostic	O
molecular	O
markers	O
and	O
potential	O
effective	O
therapeutic	O
targets	O
to	O
improve	O
patient	O
survival	O
[	O
3	O
,	O
4	O
].	O

Long	O
noncoding	O
RNAs	O
(	O
lncRNAs	O
)	O
are	O
RNA	O
transcripts	O
that	O
are	O
longer	O
than	O
200	O
nt	O
and	O
exhibit	O
limited	O
or	O
no	O
protein	O
-	O
coding	O
capacity	O
,	O
and	O
many	O
lncRNAs	O
are	O
uniquely	O
expressed	O
in	O
differentiated	O
tissues	O
or	O
specific	O
cancer	B-DS
types	O
[	O
5	O
–	O
8	O
].	O

Recent	O
discoveries	O
indicate	O
that	O
lncRNAs	O
drive	O
many	O
important	O
cancer	B-DS
phenotypes	O
by	O
interacting	O
with	O
other	O
cellular	O
macromolecules	O
,	O
including	O
DNA	O
,	O
RNA	O
,	O
and	O
protein	O
[	O
9	O
–	O
12	O
].	O

Advanced	O
studies	O
have	O
found	O
that	O
aberrant	O
lncRNA	O
expression	O
plays	O
critical	O
roles	O
in	O
hepatocarcinogenesis	O
and	O
metastasis	O
[	O
13	O
–	O
15	O
].	O

Moreover	O
,	O
MALAT1	B-GP
is	O
associated	O
with	O
tumor	B-DS
metastasis	O
and	O
can	O
predict	O
recurrence	O
after	O
liver	O
transplantation	O
[	O
16	O
,	O
17	O
].	O

Furthermore	O
,	O
UFC1	B-GP
promotes	O
HCC	B-DS
cell	O
proliferation	O
by	O
inhibiting	O
cell	O
apoptosis	O
and	O
inducing	O
cell	O
cycle	O
progression	O
[	O
18	O
].	O

Long	O
noncoding	O
RNA	O
low	O
expression	O
in	O
tumor	B-DS
(	O
lncRNA	O
-	O
LET	O
)	O
reduces	O
hepatic	O
invasion	O
and	O
abdominal	O
metastases	O
via	O
the	O
degradation	O
of	O
NF90	B-GP
[	O
19	O
],	O
and	O
MEG3	B-GP
is	O
a	O
predictive	O
biomarker	O
for	O
monitoring	O
epigenetic	O
therapy	O
[	O
20	O
].	O

In	O
addition	O
,	O
ultraconserved	O
noncoding	O
RNAs	O
(	O
ucRNAs	O
)	O
are	O
noncoding	O
RNAs	O
transcribed	O
from	O
regions	O
that	O
are	O
highly	O
conserved	O
across	O
many	O
species	O
,	O
so	O
-	O
called	O
ultraconserved	O
regions	O
[	O
21	O
].	O

Evf	O
-	O
2	O
,	O
a	O
ucRNA	O
in	O
the	O
intergenic	O
region	O
between	O
the	O
Dlx	B-GP
-	I-GP
5	I-GP
and	O
Dlx	B-GP
-	I-GP
6	I-GP
genes	O
,	O
activates	O
transcriptional	O
activity	O
by	O
directly	O
interacting	O
with	O
Dlx	B-GP
-	I-GP
2	I-GP
in	O
a	O
target	O
-	O
and	O
homeodomain	O
-	O
specific	O
manner	O
[	O
22	O
].	O

However	O
,	O
the	O
molecular	O
mechanisms	O
of	O
lncRNAs	O
remain	O
poorly	O
understood	O
and	O
warrant	O
further	O
study	O
.	O

A	O
growing	O
number	O
of	O
studies	O
have	O
focused	O
on	O
the	O
widespread	O
Hippo	B-GP
kinase	I-GP
signaling	O
inactivation	O
and	O
nuclear	O
localization	O
of	O
YAP	B-GP
in	O
epithelial	O
malignancies	O
[	O
23	O
–	O
25	O
].	O

Specifically	O
,	O
a	O
gene	O
expression	O
analysis	O
of	O
HCC	B-DS
identified	O
YAP	B-GP
as	O
an	O
important	O
“	O
driver	O
oncogene	O
”	O
[	O
26	O
],	O
and	O
the	O
Hippo	B-GP
pathway	O
is	O
a	O
highly	O
conserved	O
protein	O
kinase	B-GP
chain	O
that	O
plays	O
a	O
pivotal	O
role	O
in	O
restricting	O
tumor	B-DS
cell	O
proliferation	O
and	O
promoting	O
apoptosis	O
.	O

By	O
phosphorylating	O
YAP	B-GP
,	O
the	O
serine	B-GP
/	I-GP
threonine	I-GP
-	I-GP
protein	I-GP
kinase	I-GP
LATS1	I-GP
inhibits	O
the	O
translocation	O
of	O
YAP	B-GP
into	O
the	O
nucleus	O
and	O
decreases	O
the	O
expression	O
of	O
its	O
downstream	O
target	O
genes	O
,	O
which	O
are	O
important	O
for	O
cell	O
proliferation	O
and	O
migration	O
[	O
27	O
].	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
lncRNAs	O
regulate	O
Hippo	B-GP
kinase	I-GP
signaling	O
in	O
HCC	B-DS
remains	O
largely	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
lncRNA	O
microarray	O
to	O
identify	O
that	O
the	O
expression	O
of	O
the	O
ultraconserved	O
lncRNA	O
uc	O
.	O
134	O
was	O
significantly	O
decreased	O
in	O
the	O
highly	O
aggressive	O
HCC	B-DS
cell	O
line	O
HCCLM3	O
compared	O
with	O
MHCC97L	O
cells	O
.	O

We	O
then	O
first	O
confirmed	O
the	O
full	O
-	O
length	O
transcript	O
of	O
uc	O
.	O
134	O
using	O
5	O
′-	O
and	O
3	O
′-	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
(	O
RACE	O
)	O
analysis	O
(	O
GenBank	O
accession	O
no	O
.	O
KY355383	O
).	O

The	O
high	O
conservation	O
of	O
uc	O
.	O
134	O
implicates	O
that	O
its	O
aberrant	O
expression	O
may	O
play	O
a	O
critical	O
role	O
in	O
HCC	B-DS
progression	O
.	O

Moreover	O
,	O
in	O
situ	O
hybridization	O
(	O
ISH	O
)	O
and	O
quantitative	O
real	O
-	O
time	O
polymerase	B-GP
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
results	O
showed	O
that	O
uc	O
.	O
134	O
expression	O
significantly	O
decreased	O
in	O
HCC	B-DS
and	O
uc	O
.	O
134	O
expression	O
directly	O
correlated	O
with	O
patient	O
survival	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
the	O
overexpression	O
of	O
uc	O
.	O
134	O
suppresses	O
HCC	B-DS
cell	O
proliferation	O
and	O
invasion	O
by	O
inhibiting	O
CUL4A	B-GP
to	O
ubiquitinate	O
LATS1	B-GP
and	O
increasing	O
pYAPS127	O
expression	O
.	O

We	O
also	O
confirmed	O
that	O
uc	O
.	O
134	O
inhibits	O
the	O
expression	O
of	O
YAP	B-GP
downstream	O
target	O
genes	O
.	O

Finally	O
,	O
a	O
positive	O
relationship	O
among	O
uc	O
.	O
134	O
,	O
LATS1	B-GP
,	O
and	O
pYAPS127	O
was	O
also	O
confirmed	O
in	O
90	O
paraffin	O
-	O
embedded	O
clinical	O
samples	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
reveals	O
that	O
the	O
novel	O
lncRNA	O
uc	O
.	O
134	O
represses	O
HCC	B-DS
progression	O
by	O
inhibiting	O
the	O
CUL4A	B-GP
-	O
mediated	O
ubiquitination	O
of	O
LATS1	B-GP
and	O
increasing	O
pYAPS127	O
expression	O
.	O

Thus	O
,	O
this	O
lncRNA	O
may	O
offer	O
a	O
promising	O
treatment	O
approach	O
by	O
inhibiting	O
YAP	B-GP
and	O
activating	O
Hippo	B-GP
kinase	I-GP
signaling	O
.	O

Methods	O

Microarray	O
assay	O

Total	O
RNA	O
was	O
isolated	O
from	O
cells	O
using	O
TRIzol	O
Reagent	O
(	O
Takara	O
,	O
Dalian	O
,	O
China	O
).	O

Sample	O
labeling	O
and	O
array	O
hybridization	O
were	O
performed	O
according	O
to	O
the	O
Arraystar	O
microarray	O
-	O
based	O
gene	O
expression	O
analysis	O
protocol	O
(	O
Arraystar	O
,	O
Rockville	O
,	O
MD	O
).	O

The	O
Arraystar	O
human	B-OG
lncRNA	O
microarray	O
is	O
designed	O
for	O
the	O
global	O
profiling	O
of	O
human	B-OG
lncRNAs	O
and	O
protein	O
-	O
coding	O
mRNA	O
transcripts	O
.	O

The	O
array	O
detects	O
a	O
total	O
of	O
40	O
,	O
173	O
lncRNAs	O
.	O

The	O
lncRNAs	O
were	O
carefully	O
constructed	O
using	O
the	O
most	O
highly	O
respected	O
public	O
transcriptome	O
databases	O
(	O
RefSeq	O
,	O
UCSC	O
Known	O
Genes	O
,	O
Ensembl	O
,	O
etc	O
.),	O
as	O
well	O
as	O
landmark	O
publications	O
.	O

The	O
Arraystar	O
mRNA	O
microarray	O
provided	O
a	O
global	O
view	O
of	O
all	O
known	O
genes	O
and	O
transcripts	O
in	O
the	O
human	B-OG
genome	O
.	O

A	O
total	O
of	O
27	O
,	O
958	O
Entrez	O
Gene	O
RNAs	O
were	O
detected	O
by	O
this	O
microarray	O
.	O

The	O
content	O
was	O
sourced	O
from	O
RefSeq	O
,	O
Ensembl	O
,	O
UniGene	O
Build	O
,	O
and	O
GenBank	O
.	O

Quantile	O
normalization	O
and	O
subsequent	O
data	O
processing	O
were	O
performed	O
using	O
the	O
GeneSpring	O
GX	O
v12	O
.	O
1	O
software	O
package	O
(	O
Agilent	O
Technologies	O
).	O

After	O
quantile	O
normalization	O
of	O
the	O
raw	O
data	O
,	O
the	O
lncRNAs	O
and	O
mRNAs	O
that	O
were	O
detected	O
in	O
at	O
least	O
three	O
out	O
of	O
six	O
samples	O
were	O
chosen	O
for	O
further	O
data	O
analysis	O
.	O

Differentially	O
expressed	O
lncRNAs	O
and	O
mRNAs	O
with	O
statistical	O
significance	O
between	O
the	O
two	O
groups	O
were	O
identified	O
through	O
P	O
value	O
/	O
FDR	O
filtering	O
.	O

KEGG	O
pathway	O
analysis	O
and	O
gene	O
ontology	O
(	O
GO	O
)	O
analysis	O
were	O
applied	O
to	O
determine	O
the	O
roles	O
of	O
these	O
differentially	O
expressed	O
mRNAs	O
in	O
the	O
corresponding	O
biological	O
pathways	O
or	O
GO	O
terms	O
.	O

The	O
microarray	O
data	O
were	O
uploaded	O
in	O
the	O
Additional	O
files	O
1	O
,	O
2	O
,	O
and	O
3	O
.	O

Tissue	O
samples	O
,	O
ISH	O
,	O
immunohistochemical	O
staining	O
(	O
IHC	O
),	O
and	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O

From	O
January	O
2009	O
to	O
December	O
2013	O
,	O
170	O
human	B-OG
HCC	B-DS
samples	O
were	O
collected	O
at	O
Nanfang	O
Hospital	O
,	O
Southern	O
Medical	O
University	O
(	O
Guangzhou	O
,	O
China	O
).	O

None	O
of	O
these	O
patients	O
had	O
been	O
pretreated	O
with	O
chemotherapy	O
or	O
radiotherapy	O
before	O
undergoing	O
surgery	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Nanfang	O
Hospital	O
Institutional	O
Ethical	O
Review	O
Board	O
,	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
patient	O
.	O

LncRNA	O
uc	O
.	O
134	O
expression	O
was	O
measured	O
in	O
paraffin	O
-	O
embedded	O
samples	O
using	O
an	O
ISH	O
optimization	O
kit	O
(	O
Roche	O
,	O
Basel	O
,	O
Switzerland	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

The	O
locked	O
nucleic	O
acid	O
(	O
LNA	O
)-	O
modified	O
oligonucleotide	O
probe	O
targeting	O
uc	O
.	O
134	O
was	O
designed	O
and	O
synthesized	O
at	O
Exiqon	O
(	O
Vedbaek	O
,	O
Denmark	O
).	O

Briefly	O
,	O
HCC	B-DS
samples	O
were	O
treated	O
with	O
pepsin	B-GP
for	O
10	O
min	O
at	O
room	O
temperature	O
and	O
incubated	O
with	O
500	O
nM	O
of	O
probe	O
at	O
55	O
°	O
C	O
for	O
4	O
h	O
.	O

The	O
samples	O
were	O
incubated	O
with	O
blocking	O
solution	O
for	O
30	O
min	O
,	O
anti	O
-	O
digoxigenin	O
(	O
anti	O
-	O
DIG	O
)	O
reagent	O
was	O
applied	O
for	O
60	O
min	O
and	O
the	O
samples	O
were	O
incubated	O
with	O
AP	O
substrate	O
4	O
-	O
nitro	O
-	O
blue	O
tetrazolium	O
and	O
5	O
-	O
bromo	O
-	O
4	O
-	O
chloro	O
-	O
3	O
′-	O
indolylphosphate	O
(	O
NBT	O
-	O
BCIP	O
)	O
for	O
2	O
h	O
at	O
30	O
°	O
C	O
.	O

The	O
samples	O
were	O
then	O
mounted	O
with	O
Nuclear	O
Fast	O
Red	O
™	O
(	O
BOSTER	O
,	O
Wuhan	O
,	O
China	O
),	O
and	O
a	O
blue	O
stain	O
in	O
the	O
nucleus	O
indicated	O
a	O
positive	O
signal	O
by	O
NBT	O
-	O
BCIP	O
.	O

IHC	O
was	O
performed	O
as	O
we	O
previously	O
described	O
[	O
28	O
].	O

For	O
FISH	O
,	O
the	O
signals	O
representing	O
the	O
expression	O
of	O
LNA	O
probes	O
were	O
determined	O
using	O
the	O
tyramide	O
signal	O
amplification	O
(	O
PerkinElmer	O
,	O
USA	O
)	O
system	O
.	O

In	O
brief	O
,	O
the	O
signal	O
was	O
detected	O
by	O
incubation	O
with	O
horseradish	B-OG
peroxidase	B-GP
(	O
HRP	O
)-	O
conjugated	O
anti	O
-	O
DIG	O
antibodies	O
.	O

Then	O
,	O
the	O
signals	O
were	O
amplified	O
using	O
tetramethylrhodamine	O
(	O
TRITC	O
)-	O
conjugated	O
tyramide	O
.	O

The	O
images	O
were	O
acquired	O
with	O
a	O
fluorescence	O
microscope	O
(	O
IX70	O
,	O
Olympus	O
,	O
Japan	O
).	O

The	O
ISH	O
and	O
IHC	O
results	O
were	O
evaluated	O
by	O
two	O
individuals	O
in	O
a	O
blinded	O
fashion	O
;	O
the	O
evaluators	O
scored	O
the	O
samples	O
using	O
a	O
quick	O
scoring	O
system	O
from	O
0	O
to	O
12	O
by	O
combining	O
the	O
intensity	O
and	O
percentage	O
of	O
the	O
positive	O
signal	O
(	O
signal	O
:	O
“	O
0	O
,”	O
no	O
staining	O
;	O
“	O
1	O
,”	O
weak	O
staining	O
;	O
“	O
2	O
,”	O
intermediate	O
staining	O
;	O
and	O
“	O
3	O
,”	O
strong	O
staining	O
;	O
percentage	O
:	O
“	O
0	O
,”	O
0	O
%;	O
“	O
1	O
,”	O
1	O
–	O
25	O
%;	O
“	O
2	O
,”	O
26	O
–	O
50	O
%;	O
“	O
3	O
,”	O
51	O
–	O
75	O
%;	O
and	O
“	O
4	O
,”	O
>	O
75	O
%),	O
and	O
this	O
was	O
in	O
good	O
agreement	O
with	O
the	O
initial	O
quantification	O
.	O

An	O
optimal	O
cutoff	O
value	O
was	O
identified	O
.	O

If	O
the	O
evaluated	O
uc	O
.	O
134	O
score	O
was	O
higher	O
than	O
the	O
average	O
score	O
,	O
the	O
uc	O
.	O
134	O
expression	O
in	O
those	O
HCC	B-DS
samples	O
was	O
classified	O
as	O
high	O
;	O
otherwise	O
,	O
it	O
was	O
classified	O
as	O
low	O
.	O

To	O
account	O
for	O
inconsistencies	O
in	O
the	O
percentage	O
of	O
the	O
ISH	O
signals	O
,	O
an	O
ImageJ	O
software	O
(	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
MD	O
)	O
was	O
used	O
for	O
scoring	O
signals	O
.	O

The	O
data	O
were	O
statistically	O
analyzed	O
using	O
t	O
test	O
to	O
determine	O
the	O
differences	O
in	O
uc	O
.	O
134	O
expression	O
levels	O
between	O
different	O
groups	O
of	O
tissues	O
.	O
P	O
<	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O

In	O
vivo	O
model	O

All	O
animal	B-OG
studies	O
were	O
performed	O
with	O
the	O
approval	O
from	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
Nanfang	O
Hospital	O
.	O

Male	O
BALB	B-OG
/	I-OG
c	I-OG
nude	I-OG
mice	I-OG
(	O
age	O
,	O
4	O
–	O
6	O
weeks	O
;	O
Guangdong	O
Medical	O
Laboratory	O
Animal	O
Center	O
,	O
China	O
)	O
were	O
raised	O
under	O
specific	O
pathogen	O
-	O
free	O
conditions	O
.	O

All	O
in	O
vivo	O
experiments	O
were	O
performed	O
according	O
to	O
our	O
institution	O
’	O
s	O
guidelines	O
for	O
the	O
use	O
of	O
laboratory	O
animals	B-OG
.	O

For	O
the	O
subcutaneously	O
injected	O
tumor	B-DS
model	O
,	O
3	O
×	O
106	O
cells	O
were	O
subcutaneously	O
injected	O
into	O
the	O
left	O
flanks	O
or	O
right	O
flanks	O
of	O
mice	B-OG
.	O

After	O
4	O
weeks	O
,	O
the	O
tumors	B-DS
were	O
embedded	O
in	O
paraffin	O
for	O
ISH	O
or	O
IHC	O
.	O

For	O
the	O
lung	O
metastasis	O
model	O
,	O
2	O
×	O
106	O
cells	O
were	O
injected	O
into	O
the	O
tail	O
veins	O
.	O

We	O
monitored	O
lung	O
metastasis	O
at	O
6	O
weeks	O
to	O
quantify	O
lung	O
colonization	O
by	O
histology	O
examination	O
.	O

RACE	O
analyses	O

The	O
5	O
′	O
and	O
3	O
′-	O
RACE	O
experiments	O
were	O
performed	O
using	O
the	O
SMARTer	O
®	O
RACE	O
5	O
′/	O
3	O
′	O
Kit	O
(	O
Clontech	O
,	O
Mountain	O
View	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

Briefly	O
,	O
at	O
least	O
two	O
sets	O
of	O
primers	O
were	O
designed	O
and	O
synthesized	O
for	O
the	O
nested	O
PCR	O
.	O

The	O
RACE	O
PCR	O
products	O
were	O
separated	O
on	O
a	O
1	O
.	O
5	O
%	O
agarose	O
gel	O
.	O

The	O
results	O
of	O
electrophoresis	O
were	O
confirmed	O
,	O
and	O
the	O
amplified	O
bands	O
were	O
sequenced	O
bi	O
-	O
directionally	O
using	O
the	O
indicated	O
primers	O
.	O

The	O
gene	O
-	O
specific	O
RACE	O
primers	O
used	O
for	O
mapping	O
each	O
end	O
are	O
listed	O
in	O
Additional	O
file	O
4	O
.	O

RNA	O
isolation	O
and	O
qRT	O
-	O
PCR	O
analysis	O

Cytoplasmic	O
and	O
nuclear	O
RNA	O
fractionation	O
was	O
performed	O
using	O
the	O
PARIS	O
™	O
Kit	O
(	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
California	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

The	O
yield	O
and	O
quality	O
of	O
the	O
RNA	O
samples	O
were	O
evaluated	O
prior	O
to	O
qRT	O
-	O
PCR	O
.	O

For	O
qRT	O
-	O
PCR	O
analysis	O
,	O
total	O
RNA	O
was	O
isolated	O
from	O
the	O
cells	O
using	O
TRIzol	O
Reagent	O
(	O
Takara	O
)	O
following	O
the	O
manufacturer	O
’	O
s	O
protocol	O
.	O

First	O
-	O
strand	O
cDNA	O
synthesis	O
from	O
1	O
μg	O
of	O
total	O
RNA	O
was	O
performed	O
using	O
a	O
reverse	B-GP
transcriptase	I-GP
cDNA	O
synthesis	O
kit	O
(	O
Takara	O
).	O

The	O
resulting	O
cDNA	O
was	O
then	O
analyzed	O
by	O
qRT	O
-	O
PCR	O
using	O
a	O
SYBR	O
Green	O
PCR	O
Kit	O
(	O
Takara	O
)	O
and	O
a	O
7500	O
Fast	O
real	O
-	O
time	O
PCR	O
system	O
(	O
AB	O
Applied	O
Biosystems	O
).	O

In	O
brief	O
,	O
the	O
reaction	O
mixture	O
containing	O
500	O
ng	O
cDNA	O
,	O
the	O
forward	O
primer	O
and	O
the	O
reverse	O
primer	O
,	O
was	O
used	O
to	O
amplify	O
the	O
PCR	O
product	O
corresponding	O
to	O
the	O
human	B-OG
gene	O
.	O

The	O
experiments	O
were	O
repeated	O
at	O
least	O
three	O
times	O
independently	O
to	O
ensure	O
the	O
reproducibility	O
of	O
the	O
results	O
.	O

Human	B-OG
GAPDH	B-GP
gene	O
was	O
amplified	O
as	O
an	O
internal	O
control	O
.	O
β	B-GP
-	I-GP
actin	I-GP
and	O
U6	O
were	O
used	O
as	O
cytoplasmic	O
and	O
nuclear	O
controls	O
,	O
respectively	O
.	O

Comparative	O
quantification	O
was	O
done	O
by	O
using	O
the	O
2	O
−	O
ΔΔCt	O
method	O
.	O

The	O
primer	O
sequences	O
are	O
listed	O
in	O
Additional	O
file	O
4	O
.	O

RNA	O
immunoprecipitation	O
(	O
RIP	O
)	O

A	O
RIP	O
assay	O
was	O
performed	O
using	O
the	O
Magna	O
RIP	O
RNA	B-GP
-	I-GP
Binding	I-GP
Protein	I-GP
Immunoprecipitation	O
Kit	O
(	O
Millipore	O
,	O
MA	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

Briefly	O
,	O
whole	O
-	O
cell	O
extracts	O
prepared	O
in	O
lysis	O
buffer	O
containing	O
a	O
protease	B-GP
inhibitor	O
cocktail	O
and	O
RNase	B-GP
inhibitor	O
were	O
incubated	O
on	O
ice	O
for	O
5	O
min	O
,	O
followed	O
by	O
centrifugation	O
at	O
10	O
,	O
000g	O
and	O
4	O
°	O
C	O
for	O
10	O
min	O
.	O

Magnetic	O
beads	O
were	O
preincubated	O
with	O
5	O
ug	O
of	O
IP	O
-	O
grade	O
antibody	O
for	O
30	O
min	O
at	O
room	O
temperature	O
with	O
rotation	O
.	O

The	O
supernatant	O
was	O
added	O
to	O
bead	O
-	O
antibody	O
complexes	O
in	O
immunoprecipitation	O
buffer	O
and	O
incubated	O
at	O
4	O
°	O
C	O
overnight	O
.	O

Finally	O
,	O
the	O
RNA	O
was	O
purified	O
and	O
quantified	O
by	O
qRT	O
-	O
PCR	O
.	O

Input	O
controls	O
and	O
normal	O
rabbit	B-OG
IgG	B-GP
controls	O
were	O
assayed	O
simultaneously	O
to	O
ensure	O
that	O
the	O
signals	O
were	O
detected	O
from	O
RNA	O
that	O
was	O
specifically	O
bound	O
to	O
protein	O
.	O

RNA	O
pulldown	O
assay	O

Biotin	O
-	O
labeled	O
RNA	O
uc	O
.	O
134	O
was	O
transcribed	O
in	O
vitro	O
with	O
the	O
Biotin	O
RNA	O
Labeling	O
Mix	O
(	O
Roche	O
)	O
and	O
T7	B-GP
RNA	I-GP
polymerase	I-GP
(	O
Roche	O
)	O
and	O
then	O
treated	O
with	O
RNase	B-GP
-	O
free	O
DNase	B-GP
I	I-GP
(	O
Roche	O
)	O
and	O
0	O
.	O
2	O
M	O
EDTA	O
to	O
stop	O
the	O
reaction	O
.	O

Biotinylated	O
RNAs	O
were	O
mixed	O
with	O
streptavidin	B-GP
agarose	O
beads	O
(	O
Life	O
Technologies	O
,	O
Gaithersburg	O
,	O
MD	O
)	O
at	O
4	O
°	O
C	O
overnight	O
.	O

Total	O
cell	O
lysates	O
and	O
RNase	B-GP
inhibitor	O
were	O
added	O
to	O
each	O
binding	O
reaction	O
and	O
incubated	O
on	O
ice	O
for	O
1	O
h	O
.	O

The	O
RNA	O
–	O
protein	O
binding	O
mixture	O
was	O
boiled	O
in	O
SDS	O
buffer	O
,	O
and	O
the	O
eluted	O
proteins	O
were	O
detected	O
by	O
Western	O
blotting	O
or	O
mass	O
spectrometry	O
.	O

The	O
full	O
-	O
length	O
transcript	O
of	O
uc	O
.	O
134	O
is	O
1867	O
bp	O
in	O
length	O
;	O
Δ1	O
,	O
Δ2	O
,	O
and	O
Δ3	O
correspond	O
to	O
the	O
1	O
–	O
718	O
bp	O
,	O
719	O
–	O
1407	O
bp	O
,	O
and	O
1408	O
–	O
1867	O
bp	O
sequence	O
fragments	O
of	O
uc	O
.	O
134	O
until	O
the	O
end	O
of	O
the	O
uc	O
.	O
134	O
sequence	O
.	O

CUL4A	B-GP
was	O
cloned	O
into	O
the	O
eukaryotic	O
expression	O
vector	O
pcDNA3	O
.	O
1	O
(+)	O
with	O
a	O
C	O
-	O
terminal	O
Myc	B-GP
tag	O
and	O
translated	O
a	O
87	O
.	O
7	O
-	O
kilodalton	O
(	O
kDa	O
)	O
protein	O
.	O

CUL4A	B-GP
lacking	O
the	O
55	O
–	O
401	O
amino	O
acid	O
(	O
aa	O
)	O
region	O
was	O
cloned	O
into	O
pcDNA3	O
.	O
1	O
(+)	O
to	O
afford	O
the	O
pcDNA3	O
.	O
1	O
(+)-	O
Cul4a	B-GP
-△	O
1	O
-	O
myc	B-GP
construct	O
,	O
which	O
translated	O
a	O
46	O
.	O
94	O
-	O
kDa	O
protein	O
;	O
CUL4A	B-GP
lacking	O
the	O
400	O
–	O
671	O
aa	O
region	O
encoding	O
a	O
cullin	B-GP
homolog	O
was	O
cloned	O
into	O
pcDNA3	O
.	O
1	O
(+)	O
to	O
afford	O
the	O
pcDNA3	O
.	O
1	O
(+)-	O
Cul4a	B-GP
-△	O
2	O
-	O
myc	B-GP
construct	O
,	O
which	O
translated	O
a	O
56	O
.	O
53	O
-	O
kDa	O
protein	O
;	O
CUL4A	B-GP
lacking	O
the	O
688	O
~	O
753	O
aa	O
region	O
,	O
which	O
encodes	O
a	O
neddylation	O
domain	O
,	O
was	O
cloned	O
into	O
pcDNA3	O
.	O
1	O
(+)	O
to	O
afford	O
the	O
pcDNA3	O
.	O
1	O
(+)-	O
Cul4a	B-GP
-△	O
3	O
-	O
myc	B-GP
construct	O
,	O
which	O
translated	O
a	O
79	O
.	O
81	O
-	O
kDa	O
protein	O
;	O
CUL4A	B-GP
lacking	O
the	O
592	O
–	O
759	O
aa	O
region	O
,	O
which	O
encodes	O
the	O
winged	O
helix	O
-	O
turn	O
-	O
helix	O
DNA	O
-	O
binding	O
domain	O
(	O
WHDD	O
),	O
was	O
cloned	O
into	O
pcDNA3	O
.	O
1	O
(+)	O
to	O
afford	O
the	O
pcDNA3	O
.	O
1	O
(+)-	O
Cul4a	B-GP
-△	O
4	O
-	O
myc	B-GP
vector	O
,	O
which	O
translated	O
a	O
68	O
.	O
03	O
-	O
kDa	O
protein	O
.	O

Cycloheximide	O
(	O
CHX	O
)	O
chase	O
measurements	O
of	O
LATS1	B-GP
half	O
-	O
life	O

The	O
CUL4A	B-GP
and	O
uc	O
.	O
134	O
plasmids	O
were	O
transiently	O
transfected	O
into	O
HCC	B-DS
cells	O
using	O
jetPRIME	O
(	O
Polyplus	O
,	O
Strasbourg	O
,	O
France	O
).	O

After	O
24	O
h	O
,	O
CHX	O
(	O
10	O
ug	O
/	O
ml	O
)	O
was	O
added	O
to	O
the	O
DMEM	O
culture	O
medium	O
,	O
and	O
incubation	O
was	O
continued	O
for	O
0	O
,	O
3	O
,	O
6	O
,	O
or	O
9	O
h	O
.	O

The	O
cell	O
lysates	O
were	O
submitted	O
to	O
Western	O
blotting	O
using	O
rabbit	B-OG
anti	O
-	O
LATS1	B-GP
monoclonal	O
antibody	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Beverly	O
,	O
MA	O
),	O
and	O
Western	O
blot	O
data	O
were	O
quantified	O
using	O
the	O
ImageJ	O
software	O
.	O

Immunoprecipitation	O
(	O
IP	O
)	O
and	O
ubiquitination	O
assay	O

Ubiquitin	B-GP
,	O
LATS1	B-GP
,	O
and	O
uc	O
.	O
134	O
plasmids	O
were	O
transfected	O
into	O
cells	O
using	O
jetPRIME	O
(	O
Polyplus	O
).	O

Thirty	O
-	O
six	O
hours	O
after	O
transfection	O
,	O
10	O
nM	O
MG132	O
was	O
added	O
to	O
the	O
DMEM	O
culture	O
medium	O
and	O
incubation	O
was	O
continued	O
for	O
8	O
h	O
.	O

The	O
lysates	O
were	O
immunoprecipitated	O
with	O
the	O
indicated	O
antibodies	O
on	O
protein	B-GP
A	I-GP
/	O
G	O
beads	O
(	O
Life	O
Technologies	O
)	O
overnight	O
at	O
4	O
°	O
C	O
with	O
rotation	O
and	O
then	O
boiled	O
in	O
SDS	O
buffer	O
.	O

The	O
eluted	O
proteins	O
were	O
detected	O
by	O
Western	O
blotting	O
.	O

Statistical	O
analysis	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
the	O
SPSS	O
software	O
(	O
Chicago	O
,	O
IL	O
,	O
USA	O
).	O

Survival	O
curves	O
were	O
plotted	O
based	O
on	O
the	O
Kaplan	O
–	O
Meier	O
and	O
log	O
-	O
rank	O
tests	O
.	O

Pearson	O
’	O
s	O
chi	O
-	O
square	O
test	O
was	O
used	O
to	O
analyze	O
the	O
relationship	O
between	O
uc	O
.	O
134	O
expression	O
and	O
the	O
clinicopathologic	O
features	O
of	O
HCC	B-DS
.	O

Student	O
’	O
s	O
t	O
test	O
was	O
used	O
to	O
detect	O
significance	O
differences	O
in	O
data	O
obtained	O
from	O
qRT	O
-	O
PCR	O
experiments	O
and	O
colony	O
formation	O
assays	O
.	O

A	O
multi	O
-	O
way	O
classification	O
analysis	O
of	O
variance	O
test	O
was	O
performed	O
to	O
assess	O
data	O
obtained	O
from	O
the	O
CCK8	O
assays	O
and	O
tumor	B-DS
growth	O
.	O

Correlations	O
among	O
uc	O
.	O
134	O
expression	O
,	O
LATS1	B-GP
,	O
and	O
pYAPS127	O
were	O
analyzed	O
with	O
a	O
Spearman	O
rank	O
correlation	O
.	O
P	O
<	O
0	O
.	O
05	O
was	O
considered	O
to	O
indicate	O
a	O
significant	O
difference	O
.	O

Results	O

Decreased	O
lncRNA	O
uc	O
.	O
134	O
expression	O
in	O
HCC	B-DS
patients	O
significantly	O
correlates	O
with	O
poor	O
survival	O

Previous	O
studies	O
have	O
shown	O
that	O
lncRNA	O
expression	O
profiles	O
are	O
significantly	O
altered	O
in	O
HCC	B-DS
.	O

The	O
authors	O
of	O
a	O
previous	O
study	O
reported	O
that	O
they	O
isolated	O
a	O
parent	O
human	B-OG
HCC	B-DS
cell	O
line	O
MHCC97	O
and	O
its	O
two	O
derived	O
cell	O
lines	O
with	O
different	O
metastatic	O
potentials	O
(	O
MHCC97	O
-	O
L	O
,	O
with	O
low	O
metastatic	O
potential	O
,	O
and	O
MHCC97	O
-	O
H	O
,	O
with	O
high	O
metastatic	O
potential	O
)	O
[	O
29	O
].	O

MHCC97	O
-	O
H	O
was	O
inoculated	O
subcutaneously	O
into	O
nude	B-OG
mice	I-OG
,	O
and	O
the	O
HCCLM3	O
cell	O
line	O
was	O
established	O
from	O
lung	O
metastasis	O
in	O
the	O
mice	B-OG
.	O

These	O
HCC	B-DS
cell	O
lines	O
have	O
the	O
same	O
genetic	O
background	O
and	O
yet	O
have	O
dramatically	O
different	O
metastatic	O
behavior	O
[	O
30	O
].	O

To	O
identify	O
HCC	B-DS
metastasis	O
-	O
relevant	O
lncRNAs	O
,	O
we	O
compared	O
the	O
expression	O
profiles	O
of	O
lncRNAs	O
between	O
the	O
highly	O
aggressive	O
cell	O
line	O
HCCLM3	O
and	O
the	O
weakly	O
aggressive	O
cell	O
line	O
MHCC97L	O
using	O
human	B-OG
lncRNAs	O
microarray	O
(	O
Fig	O
.	O
1a	O
).	O

A	O
total	O
of	O
1050	O
upregulated	O
lncRNAs	O
and	O
611	O
downregulated	O
lncRNAs	O
with	O
significantly	O
differential	O
expression	O
(≥	O
3	O
.	O
0	O
-	O
fold	O
)	O
were	O
identified	O
.	O

To	O
validate	O
our	O
findings	O
from	O
the	O
microarray	O
analysis	O
,	O
the	O
top	O
four	O
upregulated	O
and	O
three	O
downregulated	O
known	O
/	O
novel	O
lncRNAs	O
were	O
detected	O
using	O
qRT	O
-	O
PCR	O
in	O
HCC	B-DS
cell	O
lines	O
and	O
the	O
immortalized	O
hepatocyte	O
cell	O
line	O
LO2	O
and	O
the	O
results	O
demonstrated	O
significant	O
differential	O
expression	O
trends	O
similar	O
to	O
those	O
predicted	O
by	O
the	O
microarray	O
(	O
Additional	O
file	O
5	O
:	O
Figure	O
S1	O
).	O

Among	O
these	O
lncRNAs	O
,	O
the	O
ultraconserved	O
noncoding	O
RNA	O
uc	O
.	O
134	O
whose	O
transcript	O
is	O
located	O
in	O
the	O
intron	O
region	O
of	O
the	O
RSRC1	B-GP
gene	O
(	O
Fig	O
.	O
1b	O
)	O
exhibited	O
the	O
greatest	O
downregulation	O
in	O
both	O
tissue	O
samples	O
and	O
HCC	B-DS
cell	O
lines	O
(	O
Fig	O
.	O
1d	O
,	O
e	O
).	O

We	O
used	O
5	O
′-	O
and	O
3	O
′-	O
RACE	O
analyses	O
to	O
identify	O
a	O
1867	O
-	O
bp	O
full	O
-	O
length	O
transcript	O
of	O
uc	O
.	O
134	O
(	O
Fig	O
.	O
1c	O
,	O
Additional	O
file	O
5	O
:	O
Figure	O
S2	O
).	O

By	O
analysis	O
of	O
cytoplasmic	O
and	O
nuclear	O
RNA	O
fractionation	O
and	O
FISH	O
experiments	O
from	O
HCC	B-DS
cells	O
,	O
we	O
observed	O
that	O
the	O
expression	O
of	O
uc	O
.	O
134	O
was	O
relatively	O
high	O
in	O
the	O
nucleus	O
(	O
Fig	O
.	O
1f	O
,	O
Additional	O
file	O
5	O
:	O
Figure	O
S3	O
).	O

ISH	O
analysis	O
was	O
used	O
to	O
determine	O
expression	O
of	O
uc	O
.	O
134	O
in	O
170	O
paraffin	O
-	O
embedded	O
surgical	O
specimens	O
of	O
HCC	B-DS
from	O
Nanfang	O
Hospital	O
.	O

The	O
expression	O
of	O
uc	O
.	O
134	O
was	O
significantly	O
downregulated	O
in	O
the	O
tumor	B-DS
tissues	O
compared	O
with	O
the	O
adjacent	O
tissues	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
1g	O
,	O
Fig	O
.	O
6a	O
).	O

Forty	O
-	O
nine	O
of	O
tumor	B-DS
tissues	O
(	O
28	O
.	O
8	O
%)	O
exhibited	O
a	O
high	O
expression	O
of	O
uc	O
.	O
134	O
,	O
and	O
the	O
other	O
121	O
cases	O
(	O
71	O
.	O
2	O
%)	O
had	O
low	O
expression	O
and	O
the	O
Kaplan	O
–	O
Meier	O
analysis	O
indicated	O
that	O
the	O
lower	O
uc	O
.	O
134	O
expression	O
was	O
related	O
to	O
poor	O
overall	O
survival	O
in	O
patients	O
with	O
HCC	B-DS
(	O
P	O
<	O
0	O
.	O
001	O
).	O

The	O
median	O
survival	O
time	O
of	O
the	O
HCC	B-DS
patients	O
with	O
low	O
uc	O
.	O
134	O
expression	O
was	O
10	O
months	O
,	O
which	O
was	O
significantly	O
shorter	O
than	O
the	O
survival	O
time	O
of	O
those	O
with	O
high	O
uc	O
.	O
134	O
expression	O
(	O
20	O
months	O
)	O
(	O
Fig	O
.	O
1h	O
).	O

Moreover	O
,	O
an	O
analysis	O
of	O
the	O
clinical	O
follow	O
-	O
up	O
data	O
combined	O
with	O
clinicopathologic	O
parameters	O
demonstrated	O
that	O
the	O
expression	O
of	O
uc	O
.	O
134	O
significantly	O
correlated	O
with	O
lymph	O
node	O
metastasis	O
(	O
P	O
=	O
0	O
.	O
005	O
)	O
and	O
tumor	B-DS
node	O
metastasis	O
(	O
TNM	O
)	O
classification	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
of	O
patients	O
with	O
HCC	B-DS
(	O
Table	O
1	O
).	O
Fig	O
.	O
1Aberrant	O
expression	O
of	O
lncRNA	O
uc	O
.	O
134	O
in	O
HCC	B-DS
.	O
a	O
Hierarchical	O
clustering	O
analysis	O
of	O
lncRNAs	O
differentially	O
expressed	O
in	O
HCCLM3	O
and	O
MHCC97L	O
HCC	B-DS
cells	O
.	O

Upregulated	O
genes	O
are	O
highlighted	O
in	O
yellow	O
,	O
and	O
downregulated	O
genes	O
are	O
in	O
blue	O
.	O

(	O
fold	O
changes	O
>	O
5	O
;	O
P	O
<	O
0	O
.	O
05	O
).	O
b	O
Transcript	O
of	O
uc	O
.	O
134	O
.	O
c	O
PCR	O
products	O
from	O
the	O
5	O
′-	O
RACE	O
and	O
3	O
′-	O
RACE	O
procedures	O
as	O
shown	O
by	O
agarose	O
gel	O
electrophoresis	O
.	O
d	O
–	O
e	O
The	O
expression	O
of	O
uc	O
.	O
134	O
was	O
analyzed	O
by	O
qRT	O
-	O
PCR	O
in	O
HCC	B-DS
tissues	O
and	O
HCC	B-DS
cells	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
;	O
**	O
P	O
<	O
0	O
.	O
01	O
;	O
and	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O
f	O
qRT	O
-	O
PCR	O
analysis	O
of	O
RNAs	O
purified	O
from	O
nuclear	O
(	O
red	O
)	O
and	O
cytosolic	O
(	O
black	O
)	O
compartments	O
in	O
Bel7402	O
cells	O
.	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O
g	O
ISH	O
assays	O
of	O
uc	O
.	O
134	O
expression	O
in	O
HCC	B-DS
paraffin	O
specimens	O
and	O
adjacent	O
nontumor	O
tissues	O
.	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O
h	O
The	O
Kaplan	O
–	O
Meier	O
method	O
was	O
used	O
to	O
assess	O
the	O
survival	O
of	O
patients	O
with	O
HCC	B-DS
,	O
and	O
the	O
log	O
-	O
rank	O
test	O
was	O
used	O
to	O
compare	O
survival	O
between	O
the	O
uc	O
.	O
134	O
-	O
low	O
and	O
lncRNAuc	O
.	O
134	O
-	O
high	O
groups	O
(	O
n	O
=	O
170	O
)	O
Table	O
1Relationship	O
between	O
lncRNA	O
uc	O
.	O
134	O
expression	O
and	O
the	O
clinical	O
characteristics	O
of	O
HCC	B-DS
patientslncRNA	O
uc	O
.	O
134	O
expressionFeatures	O
n	O
LowHigh	O
x	O
2	O
P	O
valueAll	O
cases17012149Age0	O
.	O
1690	O
.	O
412	O
<	O
50564115	O
≥	O
501148034Gender0	O
.	O
3320	O
.	O
377	O
Man14510243	O
Female25196Histological	O
grade2	O
.	O
4880	O
.	O
288	O
Well1385	O
Moderately795326	O
Poorly786018HBsAg	O
status0	O
.	O
0010	O
.	O
566	O
Negative483414	O
Positive1198435Serum	O
AFP	B-GP
(	O
ng	O
/	O
ml	O
)	O
3	O
.	O
8850	O
.	O
037	O
<	O
25674225	O
≥	O
251037924Tumor	O
size	O
(	O
cm	O
)	O
0	O
.	O
0420	O
.	O
487	O
<	O
51138132	O
≥	O
5574017Tumor	O
number4	O
.	O
0440	O
.	O
032	O
Single1459946	O
Multiple25223Lymph	O
node	O
metastasis6	O
.	O
8510	O
.	O
005	O
Negative1399346	O
Positive26242TNM	O
stage51	O
.	O
3930	O
.	O
000	O
I	O
and	O
II672740	O
III	O
and	O
IV103949	O
P	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
to	O
indicate	O
statistical	O
significance	O
.	O

The	O
P	O
values	O
were	O
calculated	O
in	O
SPSS	O
17	O
.	O
0	O
using	O
Pearson	O
’	O
s	O
chi	O
-	O
square	O
test	O

LncRNA	O
uc	O
.	O
134	O
inhibits	O
HCC	B-DS
cell	O
proliferation	O
,	O
invasion	O
,	O
and	O
metastasis	O
in	O
vitro	O
and	O
in	O
vivo	O

To	O
investigate	O
the	O
biological	O
significance	O
of	O
uc	O
.	O
134	O
in	O
the	O
progression	O
of	O
HCC	B-DS
,	O
we	O
performed	O
gain	O
-	O
of	O
-	O
function	O
and	O
loss	O
-	O
of	O
-	O
function	O
studies	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
results	O
of	O
CCK8	O
proliferation	O
assays	O
and	O
colony	O
formation	O
assays	O
showed	O
that	O
the	O
stable	O
overexpression	O
of	O
EGFP	B-GP
-	O
LV	O
-	O
uc	O
.	O
134	O
(	O
Additional	O
file	O
5	O
:	O
Figure	O
S4A	O
)	O
significantly	O
reduced	O
the	O
proliferative	O
capacity	O
of	O
HCC	B-DS
cells	O
and	O
that	O
cells	O
overexpressing	O
uc	O
.	O
134	O
formed	O
fewer	O
colonies	O
than	O
control	O
cell	O
lines	O
containing	O
the	O
empty	O
vector	O
(	O
Fig	O
.	O
2a	O
,	O
b	O
).	O

Transwell	O
and	O
scratch	O
wound	O
-	O
healing	O
assays	O
showed	O
that	O
the	O
upregulation	O
of	O
uc	O
.	O
134	O
markedly	O
reduced	O
cell	O
invasion	O
compared	O
with	O
control	O
cells	O
(	O
Fig	O
.	O
2c	O
,	O
d	O
),	O
whereas	O
the	O
knockdown	O
of	O
uc	O
.	O
134	O
by	O
EGFP	B-GP
-	O
LV	O
-	O
shRNA	O
(	O
Additional	O
file	O
5	O
:	O
Figure	O
S4B	O
)	O
promoted	O
HCC	B-DS
cell	O
growth	O
and	O
invasion	O
(	O
Additional	O
file	O
5	O
:	O
Figure	O
S5A	O
–	O
S5D	O
).	O
Fig	O
.	O
2LncRNA	O
uc	O
.	O
134	O
suppresses	O
the	O
proliferation	O
,	O
migration	O
,	O
and	O
invasion	O
of	O
HCC	B-DS
in	O
vitro	O
and	O
in	O
vivo	O
.	O
a	O
Growth	O
curves	O
of	O
indicated	O
HCC	B-DS
cells	O
that	O
overexpressed	O
uc	O
.	O
134	O
compared	O
with	O
those	O
of	O
negative	O
control	O
cells	O
and	O
untransfected	O
cells	O
were	O
determined	O
with	O
a	O
CCK8	O
proliferation	O
analysis	O
.	O

The	O
mean	O
±	O
SD	O
is	O
shown	O
for	O
five	O
independent	O
experiments	O
.	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O
b	O
Representative	O
images	O
of	O
colony	O
formation	O
assays	O
(	O
left	O
panels	O
);	O
analysis	O
of	O
the	O
number	O
of	O
colonies	O
(	O
right	O
panels	O
).	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
,	O
and	O
results	O
are	O
presented	O
as	O
mean	O
±	O
SD	O
.	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O
c	O
Invasion	O
ability	O
of	O
the	O
indicated	O
cell	O
lines	O
by	O
Transwell	O
assays	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
,	O
and	O
results	O
are	O
presented	O
as	O
mean	O
±	O
SD	O
.	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O
d	O
Representative	O
images	O
of	O
the	O
scratch	O
wound	O
-	O
healing	O
assay	O
.	O

The	O
wound	O
-	O
healing	O
percentage	O
was	O
analyzed	O
with	O
the	O
ImageJ	O
software	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
,	O
and	O
results	O
are	O
presented	O
as	O
mean	O
±	O
SD	O
.	O
**	O
P	O
<	O
0	O
.	O
01	O
and	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O
e	O
Representative	O
images	O
of	O
tumors	B-DS
formed	O
in	O
nude	B-OG
mice	I-OG
(	O
n	O
=	O
6	O
).	O
*	O
P	O
<	O
0	O
.	O
05	O
.	O
f	O
Lung	O
metastasis	O
model	O
generated	O
by	O
injecting	O
tumor	B-DS
cells	O
into	O
the	O
tail	O
veins	O
of	O
mice	B-OG
.	O

HE	O
staining	O
showing	O
the	O
number	O
and	O
volume	O
of	O
lung	O
metastases	O
in	O
each	O
group	O
(	O
n	O
=	O
6	O
);	O
**	O
P	O
<	O
0	O
.	O

01	O
and	O
***	O
P	O
<	O
0	O
.	O
001	O

For	O
in	O
vivo	O
studies	O
,	O
we	O
generated	O
a	O
xenograft	O
tumor	B-DS
model	O
by	O
subcutaneously	O
injecting	O
HCC	B-DS
cells	O
in	O
which	O
uc	O
.	O
134	O
was	O
stably	O
overexpressed	O
or	O
knocked	O
down	O
into	O
the	O
flanks	O
of	O
nude	B-OG
mice	I-OG
.	O

The	O
overexpression	O
of	O
uc	O
.	O
134	O
markedly	O
decreased	O
the	O
tumor	B-DS
growth	O
rate	O
and	O
mean	O
tumor	B-DS
volume	O
compared	O
with	O
the	O
negative	O
control	O
group	O
(	O
Fig	O
.	O
2e	O
),	O
whereas	O
silencing	O
uc	O
.	O
134	O
produced	O
the	O
opposite	O
results	O
(	O
Additional	O
file	O
5	O
:	O
Figure	O
S5E	O
).	O

Moreover	O
,	O
ISH	O
,	O
IHC	O
,	O
and	O
hematoxylin	O
-	O
eosin	O
(	O
HE	O
)	O
staining	O
were	O
performed	O
on	O
paraffin	O
-	O
embedded	O
samples	O
of	O
xenograft	O
tumors	B-DS
formed	O
by	O
cells	O
overexpressing	O
EGFP	B-GP
-	O
LV	O
-	O
uc	O
.	O
134	O
or	O
EGFP	B-GP
-	O
LV	O
-	O
shRNA	O
and	O
the	O
negative	O
control	O
cells	O
.	O

The	O
results	O
showed	O
that	O
in	O
the	O
xenograft	O
tumors	B-DS
overexpressing	O
uc	O
.	O
134	O
,	O
the	O
level	O
of	O
KI67	B-GP
expression	O
was	O
lower	O
than	O
that	O
in	O
the	O
negative	O
control	O
,	O
whereas	O
in	O
the	O
uc	O
.	O
134	O
silenced	O
tumors	B-DS
,	O
the	O
level	O
of	O
KI67	B-GP
expression	O
was	O
higher	O
(	O
Additional	O
file	O
5	O
:	O
Figure	O
S6	O
).	O

We	O
further	O
generated	O
a	O
tail	O
vein	O
xenograft	O
tumor	B-DS
model	O
by	O
injecting	O
the	O
indicated	O
cells	O
into	O
the	O
tail	O
veins	O
of	O
nude	B-OG
mice	I-OG
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
the	O
lungs	O
of	O
the	O
mice	B-OG
were	O
removed	O
for	O
HE	O
staining	O
to	O
histologically	O
examine	O
lung	O
metastases	O
.	O

LncRNA	O
uc	O
.	O
134	O
-	O
overexpressing	O
cells	O
showed	O
reduced	O
lung	O
colonization	O
ability	O
compared	O
with	O
controls	O
,	O
whereas	O
the	O
knockdown	O
of	O
uc	O
.	O
134	O
produced	O
the	O
opposite	O
results	O
(	O
Fig	O
.	O
2f	O
,	O
Additional	O
file	O
5	O
:	O
Figure	O
S5F	O
).	O

Briefly	O
,	O
our	O
studies	O
confirmed	O
that	O
uc	O
.	O
134	O
can	O
inhibit	O
HCC	B-DS
cell	O
proliferation	O
and	O
invasion	O
,	O
whereas	O
uc	O
.	O
134	O
knockdown	O
promotes	O
HCC	B-DS
growth	O
and	O
metastasis	O
,	O
suggesting	O
that	O
lncRNA	O
uc	O
.	O
134	O
may	O
have	O
a	O
critical	O
role	O
in	O
suppressing	O
the	O
development	O
of	O
HCC	B-DS
.	O

Association	O
of	O
lncRNA	O
uc	O
.	O
134	O
with	O
CUL4A	B-GP

Recently	O
,	O
several	O
studies	O
have	O
focused	O
on	O
the	O
molecular	O
regulation	O
networks	O
between	O
lncRNAs	O
and	O
proteins	O
.	O

To	O
explore	O
the	O
molecular	O
mechanisms	O
of	O
uc	O
.	O
134	O
in	O
HCC	B-DS
progression	O
,	O
we	O
performed	O
RNA	O
pulldown	O
assays	O
to	O
identify	O
proteins	O
associated	O
with	O
uc	O
.	O
134	O
.	O

After	O
10	O
%	O
SDS	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
silver	O
staining	O
,	O
the	O
differentially	O
expressed	O
bands	O
were	O
identified	O
by	O
comparison	O
with	O
the	O
antisense	O
control	O
and	O
excised	O
and	O
subjected	O
to	O
mass	O
spectrometry	O
.	O

An	O
analysis	O
of	O
RNA	O
-	O
associated	O
proteins	O
in	O
three	O
independent	O
RNA	O
pulldown	O
assays	O
followed	O
by	O
mass	O
spectrometry	O
detected	O
the	O
E3	B-GP
ubiquitin	I-GP
ligase	I-GP
CUL4A	B-GP
,	O
and	O
subsequent	O
Western	O
blot	O
analyses	O
confirmed	O
these	O
results	O
(	O
Fig	O
.	O
3a	O
).	O

We	O
also	O
performed	O
RIP	O
to	O
verify	O
the	O
candidate	O
proteins	O
pulled	O
down	O
with	O
uc	O
.	O
134	O
using	O
antibodies	O
against	O
CUL4A	B-GP
,	O
and	O
a	O
nonspecific	O
antibody	O
(	O
IgG	B-GP
)	O
was	O
used	O
as	O
a	O
control	O
.	O

The	O
data	O
showed	O
that	O
CUL4A	B-GP
directly	O
bound	O
to	O
uc	O
.	O
134	O
(	O
Fig	O
.	O
3b	O
).	O

Taken	O
together	O
,	O
these	O
results	O
confirmed	O
that	O
uc	O
.	O
134	O
and	O
CUL4A	B-GP
can	O
form	O
an	O
RNP	O
complex	O
in	O
vitro	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
lncRNAs	O
can	O
function	O
as	O
unstructured	O
sequences	O
and	O
the	O
functions	O
of	O
these	O
RNAs	O
may	O
depend	O
more	O
on	O
their	O
linear	O
sequences	O
than	O
their	O
conserved	O
secondary	O
structures	O
[	O
31	O
].	O

To	O
identify	O
the	O
unique	O
binding	O
sites	O
,	O
we	O
took	O
advantage	O
of	O
a	O
series	O
of	O
deletion	O
mutants	O
of	O
uc	O
.	O
134	O
to	O
map	O
the	O
CUL4A	B-GP
-	O
binding	O
region	O
:	O
Δ1	O
corresponds	O
to	O
the	O
region	O
between	O
nucleotides	O
1	O
–	O
718	O
of	O
uc	O
.	O
134	O
,	O
which	O
is	O
the	O
truncated	O
5	O
′	O
end	O
;	O
Δ2	O
corresponds	O
to	O
the	O
region	O
between	O
nucleotides	O
719	O
–	O
1407	O
;	O
and	O
Δ3	O
corresponds	O
to	O
the	O
region	O
between	O
nucleotides	O
1408	O
–	O
1867	O
of	O
uc	O
.	O
134	O
,	O
which	O
is	O
the	O
truncated	O
3	O
′	O
end	O
.	O

The	O
results	O
from	O
in	O
vitro	O
binding	O
assays	O
indicated	O
that	O
CUL4A	B-GP
interacted	O
with	O
a	O
460	O
-	O
nt	O
region	O
at	O
the	O
3	O
′	O
end	O
of	O
uc	O
.	O
134	O
(	O
Δ3	O
-	O
1408	O
–	O
1867	O
)	O
(	O
Fig	O
.	O
3c	O
).	O

Protein	O
domain	O
mapping	O
studies	O
demonstrated	O
that	O
uc	O
.	O
134	O
binds	O
the	O
592	O
–	O
759	O
amino	O
acid	O
(	O
aa	O
)	O
region	O
of	O
CUL4A	B-GP
(	O
Fig	O
.	O
3d	O
).	O

The	O
592	O
–	O
759	O
aa	O
region	O
of	O
CUL4A	B-GP
encodes	O
a	O
domain	O
known	O
as	O
the	O
winged	O
helix	O
-	O
turn	O
-	O
helix	O
DNA	O
-	O
binding	O
domain	O
(	O
WHDD	O
),	O
which	O
has	O
been	O
suggested	O
to	O
bind	O
DNA	O
.	O

This	O
suggestion	O
is	O
consistent	O
with	O
our	O
observation	O
that	O
the	O
WHDD	O
of	O
CUL4A	B-GP
may	O
serve	O
as	O
the	O
RNA	O
-	O
binding	O
domain	O
for	O
uc	O
.	O
134	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
uc	O
.	O
134	O
directly	O
interacts	O
with	O
CUL4A	B-GP
to	O
form	O
uc	O
.	O
134	O
-	O
CUL4A	B-GP
RNPs	O
.	O
Fig	O
.	O
3LncRNA	O
uc	O
.	O
134	O
binds	O
CUL4A	B-GP
and	O
inhibits	O
CUL4A	B-GP
nuclear	O
export	O
.	O
a	O
LncRNA	O
uc	O
.	O
134	O
-	O
associated	O
proteins	O
identified	O
by	O
RNA	O
pulldown	O
and	O
mass	O
spectrometric	O
analyses	O
in	O
HEK293T	O
cells	O
(	O
upper	O
panel	O
).	O

Western	O
blot	O
analysis	O
of	O
pulldown	O
product	O
(	O
bottom	O
panel	O
).	O
b	O
RIP	O
assays	O
in	O
HEK293T	O
cells	O
.	O

qRT	O
-	O
PCR	O
analysis	O
of	O
RIP	O
(	O
upper	O
panel	O
).	O

Agarose	O
electrophoresis	O
of	O
PCR	O
products	O
(	O
bottom	O
panel	O
).	O

Experiments	O
were	O
performed	O
in	O
triplicate	O
,	O
and	O
data	O
are	O
presented	O
as	O
mean	O
±	O
SD	O
.	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O
c	O
Immunoblot	O
(	O
IB	O
)	O
detection	O
of	O
CUL4A	B-GP
retrieved	O
by	O
in	O
vitro	O
transcribed	O
biotinylated	O
RNAs	O
corresponding	O
to	O
different	O
fragments	O
of	O
uc	O
.	O
134	O
or	O
its	O
antisense	O
sequence	O
(	O
dotted	O
line	O
)	O
in	O
HEK293T	O
cells	O
.	O
d	O
IB	O
detection	O
of	O
Myc	B-GP
-	O
tagged	O
CUL4A	B-GP
(	O
WT	O
versus	O
domain	O
truncation	O
mutants	O
)	O
precipitated	O
by	O
in	O
vitro	O
transcribed	O
biotinylated	O
uc	O
.	O
134	O
in	O
HEK293T	O
cells	O
.	O
Upper	O
panel	O
:	O
graphic	O
illustration	O
of	O
the	O
domain	O
structure	O
of	O
CUL4A	B-GP
.	O
e	O
–	O
f	O
LncRNA	O
uc	O
.	O
134	O
inhibits	O
CUL4A	B-GP
nuclear	O
export	O
as	O
demonstrated	O
by	O
immunofluorescence	O
staining	O
(	O
e	O
)	O
and	O
Western	O
blotting	O
(	O
f	O
)	O

CUL4A	B-GP
is	O
amplified	O
in	O
various	O
cancers	B-DS
,	O
which	O
suggests	O
its	O
role	O
in	O
regulating	O
cell	O
cycle	O
progression	O
,	O
transcription	O
,	O
and	O
embryonic	O
development	O
.	O

At	O
present	O
,	O
numerous	O
proteins	O
have	O
been	O
reported	O
to	O
be	O
ubiquitinated	O
by	O
CUL4A	B-GP
including	O
p53	B-GP
,	O
p21	B-GP
,	O
p27	B-GP
,	O
DICER	B-GP
,	O
and	O
LATS1	B-GP
[	O
32	O
].	O

Previous	O
studies	O
have	O
shown	O
that	O
inflammation	O
-	O
induced	O
Jak	B-GP
-	O
STAT3	B-GP
signaling	O
triggers	O
the	O
ubiquitination	O
of	O
DICER1	B-GP
in	O
cytoplasm	O
by	O
CUL4A	B-GP
to	O
promote	O
the	O
development	O
of	O
colon	B-DS
cancer	I-DS
[	O
33	O
].	O

Although	O
CUL4A	B-GP
is	O
predominantly	O
located	O
in	O
the	O
cytoplasm	O
,	O
a	O
fraction	O
of	O
CUL4A	B-GP
protein	O
resides	O
in	O
the	O
nucleus	O
and	O
mediates	O
nucleosome	O
reassembly	O
[	O
34	O
–	O
36	O
].	O

Thus	O
,	O
we	O
performed	O
Western	O
blotting	O
and	O
immunofluorescence	O
analyses	O
to	O
investigate	O
the	O
mechanism	O
by	O
which	O
uc	O
.	O
134	O
regulates	O
CUL4A	B-GP
expression	O
.	O

The	O
knockdown	O
or	O
upregulation	O
of	O
uc	O
.	O
134	O
did	O
not	O
change	O
total	O
CUL4A	B-GP
protein	O
expression	O
.	O

Interestingly	O
,	O
an	O
analysis	O
of	O
immunofluorescence	O
staining	O
suggested	O
that	O
CUL4A	B-GP
protein	O
accumulated	O
in	O
the	O
nucleus	O
when	O
uc	O
.	O
134	O
was	O
overexpressed	O
,	O
whereas	O
uc	O
.	O
134	O
knockdown	O
arrested	O
CUL4A	B-GP
protein	O
in	O
the	O
cytoplasm	O
(	O
Fig	O
.	O
3e	O
).	O

The	O
cytoplasmic	O
and	O
nuclear	O
protein	O
fractions	O
from	O
HCC	B-DS
cells	O
revealed	O
the	O
same	O
phenomenon	O
(	O
Fig	O
.	O
3f	O
).	O

LncRNA	O
uc	O
.	O
134	O
inhibits	O
the	O
CUL4A	B-GP
-	O
mediated	O
ubiquitination	O
of	O
LATS1	B-GP
to	O
regulate	O
Hippo	B-GP
kinase	I-GP
signaling	O

The	O
data	O
from	O
the	O
mRNA	O
microarray	O
and	O
GO	O
analyses	O
showed	O
that	O
the	O
overexpression	O
of	O
uc	O
.	O
134	O
significantly	O
repressed	O
ubiquitin	B-GP
protein	I-GP
ligase	I-GP
and	O
RNA	B-GP
polymerase	I-GP
activity	O
compared	O
with	O
the	O
negative	O
control	O
(	O
Fig	O
.	O
4a	O
,	O
b	O
).	O

Previous	O
studies	O
showed	O
that	O
the	O
Hippo	B-GP
pathway	O
core	O
component	O
LATS1	B-GP
contains	O
an	O
N	O
-	O
terminal	O
ubiquitin	B-GP
-	O
binding	O
domain	O
that	O
can	O
bind	O
in	O
cis	O
or	O
trans	O
to	O
C	O
-	O
terminal	O
ubiquitinated	O
sequences	O
,	O
inducing	O
conformational	O
changes	O
that	O
disturb	O
kinase	B-GP
activity	O
[	O
37	O
].	O

Since	O
CUL4A	B-GP
is	O
an	O
E3	B-GP
ligase	I-GP
that	O
targets	O
LATS1	B-GP
protein	O
for	O
ubiquitination	O
and	O
degradation	O
,	O
we	O
performed	O
an	O
immunoprecipitation	O
assay	O
using	O
either	O
anti	O
-	O
LATS1	B-GP
antibody	O
or	O
anti	O
-	O
CUL4A	B-GP
antibody	O
to	O
precipitate	O
CUL4A	B-GP
or	O
LATS1	B-GP
,	O
respectively	O
.	O

The	O
results	O
confirmed	O
the	O
interaction	O
between	O
endogenous	O
LATS1	B-GP
and	O
CUL4A	B-GP
protein	O
in	O
HCC	B-DS
cells	O
(	O
Fig	O
.	O
4c	O
).	O

Although	O
a	O
large	O
number	O
of	O
studies	O
demonstrate	O
that	O
LATS1	B-GP
plays	O
essential	O
roles	O
in	O
the	O
Hippo	B-GP
pathway	O
,	O
which	O
suppresses	O
tumorigenesis	O
and	O
stem	O
cell	O
differentiation	O
,	O
the	O
association	O
between	O
LATS1	B-GP
and	O
lncRNA	O
molecular	O
regulators	O
remains	O
largely	O
unknown	O
.	O

Thus	O
,	O
we	O
also	O
performed	O
a	O
CHX	O
chase	O
assay	O
to	O
assess	O
the	O
ability	O
of	O
uc	O
.	O
134	O
to	O
enhance	O
LATS1	B-GP
protein	O
stability	O
.	O

The	O
results	O
showed	O
that	O
LATS1	B-GP
protein	O
was	O
much	O
more	O
stable	O
in	O
cells	O
transfected	O
with	O
both	O
CUL4A	B-GP
and	O
uc	O
.	O
134	O
compared	O
with	O
cells	O
transfected	O
with	O
CUL4A	B-GP
alone	O
(	O
Fig	O
.	O
4d	O
).	O

We	O
subsequently	O
performed	O
a	O
ubiquitination	O
assay	O
,	O
which	O
showed	O
a	O
significant	O
decrease	O
in	O
polyubiquitinated	O
LATS1	B-GP
protein	O
in	O
uc	O
.	O
134	O
-	O
transfected	O
cells	O
,	O
whereas	O
the	O
knockdown	O
of	O
uc	O
.	O
134	O
increased	O
LATS1	B-GP
ubiquitination	O
(	O
Fig	O
.	O
4e	O
).	O

Previous	O
studies	O
indicated	O
that	O
polyubiquitylation	O
promotes	O
LATS1	B-GP
protein	O
degradation	O
and	O
blocks	O
its	O
kinase	B-GP
activity	O
to	O
phosphorylate	O
YAP	B-GP
[	O
37	O
].	O

Moreover	O
,	O
we	O
performed	O
a	O
Western	O
blot	O
analysis	O
,	O
which	O
showed	O
that	O
uc	O
.	O
134	O
overexpression	O
reversed	O
the	O
CUL4A	B-GP
-	O
mediated	O
decrease	O
in	O
LATS1	B-GP
expression	O
and	O
inactivation	O
of	O
Hippo	B-GP
kinase	I-GP
signaling	O
(	O
Fig	O
.	O
4f	O
).	O
Fig	O
.	O
4LncRNA	O
uc	O
.	O
134	O
inhibits	O
the	O
CUL4A	B-GP
-	O
mediated	O
ubiquitination	O
of	O
LATS1	B-GP
to	O
regulate	O
Hippo	B-GP
kinase	I-GP
signaling	O
.	O
a	O
–	O
b	O
Hierarchical	O
clustering	O
analysis	O
(	O
a	O
)	O
and	O
GO	O
analysis	O
(	O
b	O
)	O
of	O
microarray	O
data	O
for	O
HCC	B-DS
cells	O
overexpressing	O
uc	O
.	O
134	O
and	O
control	O
cells	O
.	O

Upregulated	O
genes	O
are	O
highlighted	O
in	O
yellow	O
,	O
and	O
downregulated	O
genes	O
are	O
in	O
blue	O
.	O

(	O
fold	O
changes	O
>	O
3	O
;	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
top	O
ten	O
most	O
significantly	O
enriched	O
GO	O
terms	O
in	O
differentially	O
expressed	O
genes	O
relative	O
to	O
all	O
other	O
genes	O
in	O
the	O
genome	O
are	O
shown	O
.	O
c	O
IP	O
experiment	O
.	O
d	O
The	O
overexpression	O
of	O
uc	O
.	O
134	O
prolonged	O
the	O
half	O
-	O
life	O
of	O
LATS1	B-GP
.	O

Immunoblot	O
detection	O
of	O
LATS1	B-GP
(	O
left	O
);	O
IB	O
data	O
were	O
quantified	O
using	O
the	O
ImageJ	O
software	O
(	O
right	O
).	O
Error	O
bars	O
indicate	O
the	O
mean	O
±	O
SD	O
.	O
**	O
P	O
<	O
0	O
.	O
01	O
.	O
e	O
Ubiquitination	O
assays	O
of	O
cells	O
transfected	O
with	O
uc	O
.	O
134	O
plasmid	O
in	O
Bel7402	O
cells	O
(	O
left	O
)	O
or	O
siRNA	O
in	O
QGY7701	O
cells	O
(	O
right	O
).	O

The	O
bottom	O
panels	O
depict	O
the	O
input	O
of	O
the	O
cell	O
lysates	O
.	O
f	O
Western	O
blotting	O
in	O
Bel7402	O
cells	O
showed	O
that	O
uc	O
.	O
134	O
reversed	O
the	O
CUL4A	B-GP
-	O
mediated	O
inhibition	O
of	O
Hippo	B-GP
kinase	I-GP
activity	O
.	O
g	O
Western	O
blots	O
showed	O
that	O
the	O
overexpression	O
of	O
uc	O
.	O
134	O
activates	O
Hippo	B-GP
kinase	I-GP
signaling	O
(	O
left	O
),	O
whereas	O
silencing	O
of	O
uc	O
.	O
134	O
yielded	O
opposite	O
results	O
(	O
right	O
).	O
h	O
qRT	O
-	O
PCR	O
analysis	O
of	O
cells	O
overexpressing	O
uc	O
.	O
134	O
or	O
co	O
-	O
transfected	O
with	O
YAP	B-GP
plasmids	O
compared	O
with	O
vector	O
controls	O
.	O

Experiments	O
were	O
performed	O
in	O
triplicate	O
,	O
and	O
data	O
are	O
presented	O
as	O
the	O
mean	O
±	O
SD	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
;	O
**	O
P	O
<	O
0	O
.	O
01	O
;	O
and	O
***	O
P	O
<	O
0	O
.	O
001	O

Furthermore	O
,	O
microarray	O
analysis	O
and	O
qRT	O
-	O
PCR	O
indicated	O
that	O
the	O
overexpression	O
of	O
uc	O
.	O
134	O
did	O
not	O
significantly	O
affect	O
the	O
mRNA	O
levels	O
of	O
members	O
of	O
the	O
Hippo	B-GP
signaling	O
pathway	O
,	O
such	O
as	O
Mob1	B-GP
,	O
MST1	B-GP
/	O
2	O
,	O
LATS1	B-GP
,	O
and	O
YAP	B-GP
,	O
whereas	O
the	O
mRNA	O
levels	O
of	O
YAP	B-GP
target	O
genes	O
,	O
such	O
as	O
cysteine	B-GP
-	I-GP
rich	I-GP
angiogenic	I-GP
inducer	I-GP
61	I-GP
(	O
CYR61	B-GP
),	O
c	B-GP
-	I-GP
Myc	I-GP
,	O
drosophila	B-GP
inhibitor	I-GP
of	I-GP
apoptosis	I-GP
1	I-GP
(	O
diap1	B-GP
),	O
and	O
E2F1	B-GP
,	O
were	O
significantly	O
reduced	O
.	O

In	O
addition	O
,	O
we	O
have	O
performed	O
the	O
rescue	O
experiment	O
to	O
test	O
whether	O
the	O
uc	O
.	O
134	O
-	O
mediated	O
changes	O
in	O
the	O
tumorigenesis	O
genes	O
are	O
dependent	O
on	O
YAP	B-GP
.	O

The	O
Bel7402	O
cells	O
were	O
transfected	O
with	O
the	O
uc	O
.	O
134	O
overexpressing	O
plasmid	O
alone	O
or	O
together	O
with	O
the	O
YAP	B-GP
overexpressing	O
plasmid	O
for	O
48	O
h	O
,	O
and	O
the	O
expression	O
of	O
target	O
genes	O
was	O
evaluated	O
by	O
qRT	O
-	O
qPCR	O
.	O

The	O
results	O
showed	O
that	O
there	O
was	O
no	O
reduction	O
in	O
the	O
expression	O
of	O
CYR61	B-GP
,	O
c	B-GP
-	I-GP
Myc	I-GP
,	O
diap1	B-GP
,	O
and	O
E2F1	B-GP
induced	O
by	O
uc	O
.	O
134	O
overexpression	O
in	O
the	O
YAP	B-GP
-	O
upregulated	O
cells	O
,	O
indicating	O
that	O
YAP	B-GP
is	O
responsible	O
for	O
the	O
uc	O
.	O
134	O
-	O
mediated	O
gene	O
regulation	O
(	O
Fig	O
.	O
4h	O
).	O

Moreover	O
,	O
a	O
Western	O
blot	O
analysis	O
demonstrated	O
that	O
the	O
overexpression	O
of	O
uc	O
.	O
134	O
upregulated	O
LATS1	B-GP
protein	O
expression	O
and	O
YAP	B-GP
phosphorylation	O
at	O
Ser127	O
but	O
had	O
no	O
effect	O
on	O
other	O
critical	O
proteins	O
of	O
the	O
Hippo	B-GP
kinase	I-GP
signaling	O
pathway	O
.	O

In	O
contrast	O
,	O
the	O
LATS1	B-GP
and	O
pYAPS127	O
levels	O
were	O
decreased	O
in	O
specimens	O
in	O
which	O
uc	O
.	O
134	O
expression	O
was	O
silenced	O
,	O
indicating	O
that	O
LATS1	B-GP
and	O
pYAPS127	O
are	O
downstream	O
effectors	O
of	O
uc	O
.	O
134	O
(	O
Fig	O
.	O
4g	O
).	O

Taken	O
together	O
,	O
these	O
studies	O
suggest	O
that	O
lncRNA	O
uc	O
.	O
134	O
inhibits	O
CUL4A	B-GP
translocation	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
to	O
disrupt	O
polyubiquitin	O
chains	O
,	O
which	O
activates	O
the	O
Hippo	B-GP
kinase	I-GP
signaling	O
and	O
silences	O
target	O
genes	O
of	O
YAP	B-GP
by	O
increasing	O
the	O
stability	O
of	O
LATS1	B-GP
protein	O
.	O

LncRNA	O
uc	O
.	O
134	O
represses	O
HCC	B-DS
proliferation	O
and	O
metastasis	O
via	O
the	O
uc	O
.	O
134	O
-	O
CUL4A	B-GP
-	O
Hippo	B-GP
axis	O

A	O
Western	O
blot	O
analysis	O
demonstrated	O
that	O
the	O
overexpression	O
of	O
uc	O
.	O
134	O
upregulated	O
LATS1	B-GP
protein	O
expression	O
and	O
YAP	B-GP
phosphorylation	O
at	O
Ser127	O
,	O
indicating	O
that	O
LATS1	B-GP
and	O
pYAPS127	O
are	O
downstream	O
effectors	O
of	O
uc	O
.	O
134	O
.	O

We	O
then	O
assessed	O
the	O
ability	O
of	O
CUL4A	B-GP
to	O
overcome	O
the	O
uc	O
.	O
134	O
-	O
mediated	O
activation	O
of	O
Hippo	B-GP
kinase	I-GP
signaling	O
in	O
HCC	B-DS
cells	O
.	O

Notably	O
,	O
Western	O
blotting	O
showed	O
that	O
the	O
overexpression	O
of	O
CUL4A	B-GP
inhibited	O
the	O
uc	O
.	O
134	O
-	O
mediated	O
increases	O
in	O
LATS1	B-GP
and	O
YAPS127	O
phosphorylation	O
,	O
whereas	O
the	O
knockdown	O
of	O
CUL4A	B-GP
reversed	O
the	O
si	O
-	O
uc	O
.	O
134	O
-	O
mediated	O
repression	O
of	O
LATS1	B-GP
and	O
inactivation	O
of	O
Hippo	B-GP
kinase	I-GP
signaling	O
(	O
Fig	O
.	O
5a	O
,	O
Additional	O
file	O
5	O
:	O
Figure	O
S4C	O
).	O

The	O
biological	O
function	O
analysis	O
showed	O
that	O
CUL4A	B-GP
overexpression	O
abrogated	O
the	O
uc	O
.	O
134	O
-	O
mediated	O
repression	O
HCC	B-DS
cell	O
proliferation	O
and	O
invasion	O
,	O
whereas	O
CUL4A	B-GP
knockdown	O
yielded	O
the	O
opposite	O
results	O
(	O
Fig	O
.	O
5b	O
,	O
c	O
).	O

Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
lncRNA	O
uc	O
.	O
134	O
plays	O
a	O
key	O
role	O
in	O
suppressing	O
the	O
proliferation	O
,	O
invasion	O
,	O
and	O
metastasis	O
of	O
HCC	B-DS
by	O
blocking	O
CUL4A	B-GP
nuclear	O
export	O
to	O
ubiquitinate	O
LATS1	B-GP
and	O
increasing	O
YAPS127	O
phosphorylation	O
,	O
which	O
implicates	O
the	O
lncRNA	O
uc	O
.	O
134	O
-	O
CUL4A	B-GP
-	O
Hippo	B-GP
axis	O
as	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
HCC	B-DS
.	O
Fig	O
.	O
5LncRNA	O
uc	O
.	O
134	O
represses	O
HCC	B-DS
proliferation	O
and	O
metastasis	O
via	O
the	O
uc	O
.	O
134	O
-	O
CUL4A	B-GP
-	O
Hippo	B-GP
axis	O
.	O
a	O
Western	O
blot	O
showing	O
that	O
CUL4A	B-GP
abrogated	O
the	O
uc	O
.	O
134	O
-	O
mediated	O
activation	O
of	O
Hippo	B-GP
kinase	I-GP
signaling	O
(	O
left	O
),	O
whereas	O
the	O
knockdown	O
of	O
CUL4A	B-GP
reversed	O
the	O
si	O
-	O
uc	O
.	O
134	O
-	O
mediated	O
repression	O
of	O
LATS1	B-GP
and	O
inactivation	O
of	O
YAP	B-GP
(	O
right	O
).	O
b	O
A	O
Transwell	O
analysis	O
showed	O
that	O
CUL4A	B-GP
overexpression	O
abrogated	O
the	O
uc	O
.	O
134	O
-	O
mediated	O
repression	O
of	O
HCC	B-DS
cell	O
invasion	O
(	O
upper	O
),	O
whereas	O
CUL4A	B-GP
knockdown	O
yielded	O
the	O
opposite	O
results	O
(	O
lower	O
).	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
,	O
and	O
results	O
are	O
presented	O
as	O
mean	O
±	O
SD	O
.	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O
c	O
A	O
CCK8	O
proliferation	O
analysis	O
showed	O
that	O
the	O
transfection	O
of	O
CUL4A	B-GP
plasmid	O
or	O
LATS1	B-GP
-	O
specific	O
siRNA	O
abolished	O
the	O
uc	O
.	O
134	O
-	O
mediated	O
growth	O
inhibition	O
(	O
left	O
),	O
whereas	O
the	O
transfection	O
of	O
siCUL4A	O
or	O
LATS1	B-GP
plasmid	O
yielded	O
opposite	O
results	O
(	O
right	O
).	O

The	O
mean	O
±	O
SD	O
is	O
shown	O
for	O
five	O
independent	O
experiments	O
.	O
**	O
P	O
<	O
0	O
.	O
01	O
;	O
and	O
***	O
P	O
<	O
0	O
.	O
001	O

LncRNA	O
uc	O
.	O
134	O
expression	O
positively	O
correlates	O
with	O
LATS1	B-GP
and	O
pYAPS127	O
levels	O
in	O
HCC	B-DS
patient	O
samples	O

We	O
studied	O
correlations	O
among	O
uc	O
.	O
134	O
,	O
LATS1	B-GP
,	O
and	O
pYAPS127	O
expression	O
by	O
ISH	O
and	O
IHC	O
in	O
paraffin	O
-	O
embedded	O
samples	O
from	O
patients	O
with	O
HCC	B-DS
(	O
Fig	O
.	O
6a	O
).	O

IHC	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
expression	O
of	O
LATS1	B-GP
or	O
pYAPS127	O
in	O
90	O
paraffin	O
-	O
embedded	O
surgical	O
specimens	O
of	O
HCC	B-DS
from	O
Nanfang	O
Hospital	O
.	O

The	O
expression	O
of	O
LATS1	B-GP
was	O
significantly	O
downregulated	O
in	O
the	O
tumor	B-DS
tissues	O
compared	O
with	O
the	O
adjacent	O
tissues	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
6a	O
,	O
Additional	O
file	O
5	O
:	O
Figure	O
S7A	O
),	O
and	O
the	O
Kaplan	O
–	O
Meier	O
analysis	O
indicated	O
that	O
the	O
lower	O
LATS1	B-GP
expression	O
was	O
related	O
to	O
poor	O
overall	O
survival	O
in	O
patients	O
with	O
HCC	B-DS
(	O
P	O
=	O
0	O
.	O
032	O
).	O

The	O
median	O
survival	O
time	O
of	O
the	O
HCC	B-DS
patients	O
with	O
low	O
LATS1	B-GP
expression	O
was	O
16	O
months	O
,	O
which	O
was	O
significantly	O
shorter	O
than	O
those	O
with	O
high	O
LATS1	B-GP
expression	O
(	O
49	O
months	O
)	O
(	O
Additional	O
file	O
5	O
:	O
Figure	O
S7C	O
).	O

In	O
addition	O
,	O
the	O
expression	O
of	O
pYAPS127	O
was	O
also	O
significantly	O
downregulated	O
in	O
the	O
tumors	B-DS
compared	O
with	O
the	O
adjacent	O
tissues	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Fig	O
.	O
6a	O
,	O
Additional	O
file	O
5	O
:	O
Figure	O
S7B	O
).	O

By	O
the	O
Kaplan	O
–	O
Meier	O
analysis	O
,	O
it	O
was	O
observed	O
that	O
the	O
low	O
pYAPS127	O
protein	O
level	O
was	O
a	O
significant	O
prognostic	O
factor	O
for	O
poor	O
overall	O
survival	O
in	O
patients	O
with	O
HCC	B-DS
(	O
P	O
=	O
0	O
.	O
01	O
).	O

The	O
median	O
survival	O
time	O
of	O
the	O
HCC	B-DS
patients	O
with	O
low	O
pYAPS127	O
expression	O
was	O
16	O
months	O
,	O
which	O
was	O
significantly	O
shorter	O
than	O
those	O
with	O
high	O
pYAPS127	O
expression	O
(	O
50	O
months	O
)	O
(	O
Additional	O
file	O
5	O
:	O
Figure	O
S7D	O
).	O

Together	O
,	O
these	O
results	O
clearly	O
show	O
that	O
the	O
expressions	O
of	O
LATS1	B-GP
and	O
pYAPS127	O
are	O
reduced	O
in	O
the	O
HCC	B-DS
tissues	O
compared	O
with	O
the	O
adjacent	O
tissues	O
,	O
and	O
low	O
LATS1	B-GP
or	O
pYAPS127	O
expression	O
is	O
associated	O
with	O
worse	O
prognosis	O
.	O

In	O
addition	O
,	O
correlations	O
among	O
the	O
expression	O
of	O
uc	O
.	O
134	O
,	O
LATS1	B-GP
,	O
and	O
pYAPS127	O
were	O
analyzed	O
with	O
a	O
Spearman	O
’	O
s	O
rank	O
correlation	O
.	O

The	O
scatter	O
plot	O
showed	O
positive	O
relationships	O
among	O
uc	O
.	O
134	O
,	O
LATS1	B-GP
(	O
r	O
2	O
=	O
0	O
.	O
509	O
;	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
pYAPS127	O
(	O
r	O
2	O
=	O
0	O
.	O
435	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
a	O
positive	O
relationship	O
between	O
LATS1	B-GP
and	O
pYAPS127	O
(	O
r	O
2	O
=	O
0	O
.	O
614	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
90	O
HCC	B-DS
specimens	O
(	O
Fig	O
.	O
6b	O
–	O
d	O
).	O

Collectively	O
,	O
our	O
data	O
indicate	O
that	O
a	O
460	O
-	O
nt	O
region	O
of	O
uc	O
.	O
134	O
(	O
Δ3	O
-	O
1408	O
–	O
1867	O
)	O
binds	O
to	O
the	O
WHDD	O
(	O
592	O
–	O
759	O
aa	O
region	O
)	O
domain	O
of	O
CUL4A	B-GP
to	O
inhibit	O
CUL4A	B-GP
-	O
mediated	O
ubiquitination	O
of	O
LATS1	B-GP
and	O
activate	O
Hippo	B-GP
kinase	I-GP
signaling	O
.	O

Thus	O
,	O
the	O
lncRNA	O
uc	O
.	O
134	O
-	O
CUL4A	B-GP
-	O
Hippo	B-GP
axis	O
may	O
offer	O
a	O
promising	O
approach	O
for	O
the	O
treatment	O
of	O
HCC	B-DS
(	O
Fig	O
.	O
6e	O
).	O
Fig	O
.	O
6Expression	O
levels	O
of	O
lncRNA	O
uc	O
.	O
134	O
,	O
LATS1	B-GP
,	O
and	O
pYAPS127	O
positively	O
correlated	O
in	O
samples	O
from	O
patients	O
with	O
HCC	B-DS
.	O
a	O
The	O
ISH	O
and	O
IHC	O
staining	O
of	O
HCC	B-DS
paraffin	O
-	O
embedded	O
samples	O
showed	O
that	O
the	O
expression	O
levels	O
of	O
uc	O
.	O
134	O
,	O
LATS1	B-GP
,	O
and	O
pYAPS127	O
were	O
significantly	O
downregulated	O
in	O
HCC	B-DS
(	O
200	O
×	O
magnification	O
,	O
n	O
=	O
90	O
).	O
b	O
–	O
d	O
A	O
scatter	O
diagram	O
showed	O
positive	O
correlations	O
among	O
uc	O
.	O
134	O
and	O
LATS1	B-GP
or	O
pYAPS127	O
.	O
e	O
A	O
model	O
for	O
the	O
regulatory	O
mechanisms	O
of	O
uc	O
.	O
134	O
in	O
HCC	B-DS

Discussion	O

HCC	B-DS
is	O
a	O
leading	O
cause	O
of	O
cancer	B-DS
-	O
related	O
death	O
worldwide	O
,	O
and	O
tumor	B-DS
recurrence	O
and	O
metastasis	O
are	O
major	O
factors	O
that	O
contribute	O
to	O
the	O
poor	O
prognosis	O
of	O
patients	O
with	O
HCC	B-DS
.	O

Moreover	O
,	O
recent	O
research	O
has	O
greatly	O
advanced	O
our	O
understanding	O
of	O
the	O
essential	O
role	O
of	O
lncRNAs	O
in	O
HCC	B-DS
[	O
10	O
,	O
12	O
].	O

Although	O
thousands	O
of	O
lncRNAs	O
have	O
been	O
functionally	O
characterized	O
,	O
the	O
vast	O
majority	O
of	O
members	O
of	O
this	O
RNA	O
class	O
have	O
not	O
been	O
thoroughly	O
described	O
.	O

UcRNAs	O
are	O
noncoding	O
RNAs	O
transcribed	O
from	O
regions	O
that	O
are	O
highly	O
conserved	O
across	O
humans	B-OG
,	O
mice	B-OG
,	O
and	O
rats	B-OG
,	O
so	O
-	O
called	O
ultraconserved	O
regions	O
(	O
UCRs	O
).	O

UCRs	O
are	O
usually	O
located	O
at	O
genomic	O
regions	O
that	O
are	O
involved	O
in	O
cancer	B-DS
and	O
differentially	O
expressed	O
in	O
carcinomas	B-DS
.	O

Here	O
,	O
we	O
used	O
lncRNA	O
microarrays	O
to	O
identify	O
that	O
the	O
expression	O
of	O
an	O
ultraconserved	O
lncRNA	O
,	O
uc	O
.	O
134	O
,	O
was	O
significantly	O
decreased	O
in	O
the	O
highly	O
aggressive	O
HCC	B-DS
cell	O
line	O
HCCLM3	O
compared	O
with	O
MHCC97L	O
cells	O
.	O

We	O
first	O
confirmed	O
the	O
full	O
-	O
length	O
transcript	O
of	O
uc	O
.	O
134	O
using	O
5	O
′-	O
and	O
3	O
′-	O
RACE	O
analyses	O
,	O
and	O
qRT	O
-	O
PCR	O
showed	O
that	O
uc	O
.	O
134	O
expression	O
was	O
reduced	O
in	O
both	O
tissue	O
samples	O
and	O
HCC	B-DS
cell	O
lines	O
.	O

Thus	O
,	O
the	O
decreased	O
expression	O
of	O
uc	O
.	O
134	O
in	O
HCC	B-DS
,	O
especially	O
in	O
highly	O
aggressive	O
cell	O
lines	O
,	O
indicates	O
that	O
uc	O
.	O
134	O
may	O
be	O
a	O
promising	O
marker	O
for	O
HCC	B-DS
.	O

ISH	O
results	O
showed	O
that	O
the	O
expression	O
of	O
uc	O
.	O
134	O
was	O
significantly	O
downregulated	O
in	O
170	O
paraffin	O
-	O
embedded	O
HCC	B-DS
specimens	O
and	O
decreased	O
uc	O
.	O
134	O
expression	O
was	O
related	O
to	O
poor	O
survival	O
in	O
patients	O
with	O
HCC	B-DS
.	O

Moreover	O
,	O
an	O
analysis	O
of	O
clinical	O
follow	O
-	O
up	O
data	O
and	O
clinicopathologic	O
parameters	O
demonstrated	O
that	O
the	O
expression	O
of	O
uc	O
.	O
134	O
significantly	O
correlated	O
with	O
lymph	O
node	O
metastasis	O
(	O
P	O
=	O
0	O
.	O
005	O
)	O
and	O
TNM	O
classification	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
patients	O
with	O
HCC	B-DS
.	O

Cancer	B-DS
is	O
fundamentally	O
a	O
genetic	B-DS
disease	I-DS
with	O
numerous	O
alterations	O
in	O
DNA	O
,	O
RNA	O
,	O
and	O
proteins	O
that	O
support	O
tumor	B-DS
growth	O
and	O
development	O
[	O
38	O
].	O

The	O
molecular	O
and	O
cellular	O
characteristics	O
of	O
cancer	B-DS
-	O
associated	O
lncRNAs	O
are	O
under	O
distinct	O
regulatory	O
regimes	O
that	O
are	O
different	O
from	O
physiological	O
conditions	O
[	O
12	O
].	O

Although	O
numerous	O
studies	O
have	O
used	O
gene	O
overexpression	O
plasmids	O
or	O
lentiviral	O
vectors	O
to	O
evaluate	O
the	O
functions	O
of	O
tumor	B-DS
-	O
suppressor	O
genes	O
,	O
the	O
cellular	O
toxicities	O
of	O
these	O
gene	O
carriers	O
are	O
inevitable	O
.	O

Therefore	O
,	O
a	O
knockdown	O
model	O
such	O
as	O
RNAi	O
is	O
necessary	O
.	O

In	O
our	O
study	O
,	O
we	O
performed	O
gain	O
-	O
of	O
-	O
function	O
and	O
loss	O
-	O
of	O
-	O
function	O
studies	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
to	O
demonstrate	O
that	O
uc	O
.	O
134	O
plays	O
a	O
critical	O
role	O
in	O
the	O
inhibition	O
of	O
cell	O
proliferation	O
,	O
invasion	O
,	O
and	O
metastasis	O
in	O
HCC	B-DS
.	O

Ideally	O
,	O
Tet	O
-	O
Off	O
and	O
Tet	O
-	O
On	O
systems	O
will	O
fulfill	O
the	O
requirements	O
for	O
the	O
quantitative	O
and	O
temporal	O
control	O
of	O
gene	O
expression	O
via	O
nontoxic	O
effector	O
molecules	O
,	O
and	O
these	O
will	O
be	O
used	O
in	O
the	O
future	O
[	O
39	O
].	O

A	O
growing	O
number	O
of	O
studies	O
confirm	O
that	O
the	O
Hippo	B-GP
kinase	I-GP
signaling	O
,	O
which	O
is	O
critical	O
for	O
tumor	B-DS
progression	O
and	O
invasion	O
,	O
is	O
inactivated	O
in	O
many	O
cancers	B-DS
.	O

The	O
core	O
components	O
of	O
Hippo	B-GP
kinase	I-GP
signaling	O
pathway	O
are	O
conserved	O
in	O
mammals	B-OG
and	O
have	O
a	O
complex	O
network	O
of	O
crosstalk	O
with	O
other	O
important	O
signaling	O
pathways	O
,	O
such	O
as	O
the	O
TGFβ	B-GP
/	O
SMAD	B-GP
,	O
WNT	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
,	O
PI3	B-GP
-	I-GP
kinase	I-GP
/	O
AKT	B-GP
,	O
Hedgehog	B-GP
,	O
Jak	B-GP
/	O
Stat	B-GP
,	O
and	O
Notch	B-GP
pathways	O
[	O
40	O
].	O

A	O
previous	O
study	O
confirmed	O
that	O
YAP	B-GP
increases	O
resistance	O
to	O
RAF	B-GP
-	O
and	O
MEK	B-GP
-	O
targeted	O
cancer	B-DS
therapies	O
[	O
41	O
].	O

Moreover	O
,	O
the	O
serine	B-GP
/	I-GP
threonine	I-GP
kinase	I-GP
LATS1	B-GP
is	O
a	O
core	O
kinase	B-GP
of	O
Hippo	B-GP
kinase	I-GP
signaling	O
pathway	O
and	O
plays	O
important	O
roles	O
in	O
tumor	B-DS
proliferation	O
,	O
apoptosis	O
,	O
and	O
stem	O
cell	O
differentiation	O
.	O

A	O
previous	O
study	O
showed	O
that	O
Merlin	B-GP
activates	O
Hippo	B-GP
kinase	I-GP
signaling	O
by	O
inhibiting	O
CRL4DCAF1	O
,	O
an	O
E3	B-GP
ubiquitin	I-GP
ligase	I-GP
of	O
the	O
CRL4	B-GP
complex	O
[	O
42	O
].	O

CUL4A	B-GP
is	O
a	O
core	O
component	O
of	O
the	O
CRL4	B-GP
complex	O
,	O
and	O
its	O
N	O
-	O
terminus	O
associates	O
with	O
a	O
cullin	B-GP
-	O
specific	O
adaptor	O
protein	O
to	O
recruit	O
a	O
large	O
number	O
of	O
substrate	O
proteins	O
.	O

CUL4A	B-GP
can	O
interact	O
with	O
LATS1	B-GP
protein	O
and	O
enhance	O
its	O
proteasomal	O
degradation	O
.	O

Another	O
study	O
demonstrated	O
that	O
the	O
de	O
-	O
repression	O
of	O
CRL4DCAF1	O
inhibited	O
the	O
activation	O
of	O
the	O
Hippo	B-GP
pathway	O
by	O
directly	O
binding	O
to	O
and	O
ubiquitinating	O
LATS1	B-GP
/	O
2	O
in	O
NF2	B-GP
-	O
mutant	O
tumors	B-DS
in	O
the	O
nucleus	O
[	O
37	O
].	O

However	O
,	O
the	O
mechanism	O
that	O
regulates	O
LATS1	B-GP
at	O
the	O
lncRNA	O
level	O
remains	O
unknown	O
.	O

We	O
performed	O
RNA	O
pulldown	O
and	O
RIP	O
assays	O
,	O
which	O
showed	O
that	O
uc	O
.	O
134	O
bound	O
the	O
E3	B-GP
ligase	I-GP
CUL4A	B-GP
.	O

Protein	O
domain	O
mapping	O
and	O
deletion	O
mutation	O
analyses	O
identified	O
a	O
592	O
–	O
759	O
aa	O
region	O
of	O
CUL4A	B-GP
,	O
which	O
encodes	O
a	O
WHDD	O
domain	O
,	O
that	O
binds	O
a	O
460	O
-	O
nt	O
region	O
at	O
the	O
3	O
′	O
end	O
of	O
uc	O
.	O
134	O
(	O
Δ3	O
-	O
1408	O
–	O
1867	O
).	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
uc	O
.	O
134	O
inhibited	O
the	O
translocation	O
of	O
CUL4A	B-GP
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
,	O
which	O
inhibits	O
the	O
CUL4A	B-GP
-	O
mediated	O
ubiquitination	O
and	O
degradation	O
of	O
LATS1	B-GP
in	O
the	O
cytoplasm	O
and	O
increases	O
YAPS127	O
phosphorylation	O
.	O

LncRNAs	O
regulate	O
many	O
important	O
activities	O
in	O
cancer	B-DS
through	O
their	O
interactions	O
with	O
DNA	O
,	O
RNA	O
,	O
and	O
proteins	O
.	O

The	O
mechanisms	O
through	O
which	O
lncRNAs	O
interact	O
with	O
proteins	O
to	O
regulate	O
protein	O
-	O
protein	O
interactions	O
or	O
modulate	O
the	O
subcellular	O
transport	O
of	O
proteins	O
are	O
largely	O
unknown	O
[	O
43	O
].	O

It	O
remains	O
to	O
be	O
investigated	O
whether	O
the	O
uc	O
.	O
134	O
-	O
CUL4A	B-GP
RNP	O
can	O
be	O
retained	O
in	O
the	O
nucleus	O
through	O
binding	O
with	O
other	O
nuclear	O
proteins	O
or	O
by	O
forming	O
an	O
RNA	O
–	O
DNA	O
triplex	O
.	O

As	O
a	O
co	O
-	O
activator	O
of	O
transcription	O
,	O
YAP	B-GP
binds	O
to	O
the	O
TEAD	B-GP
complex	O
and	O
elevates	O
the	O
levels	O
of	O
numerous	O
target	O
genes	O
to	O
promote	O
tumor	B-DS
proliferation	O
and	O
metastasis	O
.	O

CYR61	B-GP
is	O
overexpressed	O
in	O
various	O
cancers	B-DS
and	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
tumor	B-DS
growth	O
and	O
vascularization	O
.	O

Previous	O
reports	O
showed	O
that	O
the	O
YAP	B-GP
-	O
dependent	O
expression	O
of	O
CYR61	B-GP
increased	O
the	O
invasive	O
activity	O
of	O
the	O
glioblastoma	B-DS
cells	O
[	O
44	O
].	O

Inactivation	O
of	O
c	B-GP
-	I-GP
Myc	I-GP
results	O
in	O
tumor	B-DS
dormancy	O
and	O
pluripotent	O
differentiation	O
of	O
tumor	B-DS
cells	O
.	O

YAP	B-GP
has	O
been	O
reported	O
to	O
promote	O
the	O
transcriptional	O
activity	O
of	O
c	B-GP
-	I-GP
Myc	I-GP
via	O
interaction	O
with	O
c	B-GP
-	I-GP
Abl	I-GP
in	O
HCC	B-DS
[	O
45	O
].	O

diap1	B-GP
directly	O
binds	O
to	O
and	O
inhibits	O
caspases	B-GP
to	O
suppress	O
apoptosis	O
.	O

Activation	O
of	O
YAP	B-GP
increased	O
the	O
transcription	O
of	O
diap1	B-GP
,	O
cell	O
proliferation	O
,	O
and	O
tissue	O
overgrowth	O
[	O
46	O
,	O
47	O
].	O

A	O
previous	O
study	O
has	O
shown	O
that	O
Yorkie	O
promotes	O
the	O
overgrowth	O
of	O
drosophila	O
neuroepithelial	O
cells	O
and	O
delays	O
their	O
differentiation	O
through	O
the	O
regulation	O
of	O
the	O
cell	O
cycle	O
regulator	O
E2F1	B-GP
,	O
which	O
plays	O
key	O
roles	O
in	O
cell	O
cycle	O
progression	O
and	O
cell	O
differentiation	O
in	O
HCC	B-DS
[	O
48	O
,	O
49	O
].	O

We	O
performed	O
microarray	O
analysis	O
and	O
qRT	O
-	O
PCR	O
indicated	O
that	O
overexpression	O
of	O
uc	O
.	O
134	O
significantly	O
decreased	O
the	O
expression	O
of	O
YAP	B-GP
target	O
genes	O
.	O

In	O
addition	O
,	O
when	O
we	O
co	O
-	O
transfected	O
the	O
HCC	B-DS
cells	O
with	O
plasmids	O
expressing	O
YAP	B-GP
and	O
those	O
expressing	O
uc	O
.	O
134	O
,	O
the	O
decrease	O
in	O
the	O
mRNA	O
level	O
of	O
CYR61	B-GP
,	O
c	B-GP
-	I-GP
Myc	I-GP
,	O
diap1	B-GP
,	O
and	O
E2F1	B-GP
was	O
reversed	O
by	O
YAP	B-GP
,	O
indicating	O
that	O
YAP	B-GP
is	O
responsible	O
for	O
the	O
uc	O
.	O
134	O
-	O
mediated	O
gene	O
regulation	O
.	O

Finally	O
,	O
a	O
positive	O
correlation	O
between	O
uc	O
.	O
134	O
,	O
LATS1	B-GP
,	O
and	O
pYAPS127	O
was	O
confirmed	O
in	O
90	O
paraffin	O
-	O
embedded	O
samples	O
by	O
ISH	O
and	O
IHC	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
uc	O
.	O
134	O
increased	O
Hippo	B-GP
kinase	I-GP
activity	O
and	O
repressed	O
the	O
downstream	O
target	O
genes	O
of	O
YAP	B-GP
by	O
inhibiting	O
CUL4A	B-GP
-	O
mediated	O
ubiquitination	O
and	O
degradation	O
of	O
LATS1	B-GP
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
study	O
is	O
the	O
first	O
to	O
investigate	O
the	O
critical	O
role	O
of	O
lncRNAs	O
in	O
the	O
regulation	O
of	O
LATS1	B-GP
in	O
HCC	B-DS
.	O

Thus	O
,	O
this	O
lncRNA	O
may	O
offer	O
a	O
promising	O
approach	O
for	O
HCC	B-DS
therapy	O
by	O
inhibiting	O
YAP	B-GP
and	O
activating	O
Hippo	B-GP
kinase	I-GP
signaling	O
.	O

Previous	O
studies	O
have	O
clarified	O
that	O
the	O
major	O
risk	O
factor	O
for	O
HCC	B-DS
in	O
China	O
is	O
hepatitis	B-DS
B	I-DS
virus	I-DS
(	I-DS
HBV	I-DS
)	I-DS
infection	I-DS
,	O
although	O
hepatitis	B-DS
C	I-DS
virus	I-DS
infection	I-DS
and	O
exposure	O
to	O
toxic	O
chemical	O
substances	O
also	O
contribute	O
to	O
the	O
incidence	O
of	O
HCC	B-DS
.	O

The	O
lncRNA	O
MEG3	B-GP
is	O
regulated	O
by	O
miR	O
-	O
29a	O
in	O
a	O
methylation	O
-	O
dependent	O
,	O
tissue	O
-	O
specific	O
manner	O
,	O
and	O
it	O
contributes	O
to	O
the	O
growth	O
of	O
HCC	B-DS
[	O
20	O
].	O

Histone	B-GP
deacetylase	I-GP
3	I-GP
(	O
HDAC3	B-GP
)	O
is	O
involved	O
in	O
the	O
suppression	O
of	O
HCC	B-DS
-	O
related	O
lncRNA	O
-	O
LET	O
[	O
19	O
].	O

The	O
aberrant	O
expression	O
of	O
lncRNA	O
uc	O
.	O
134	O
in	O
HCC	B-DS
may	O
be	O
mediated	O
by	O
HBV	B-DS
infection	I-DS
at	O
the	O
transcriptional	O
level	O
,	O
post	O
-	O
transcriptional	O
level	O
,	O
or	O
by	O
epigenetic	O
regulations	O
such	O
as	O
DNA	O
methylation	O
or	O
histone	O
deacetylation	O
[	O
50	O
].	O

In	O
our	O
study	O
,	O
we	O
report	O
that	O
the	O
ultraconserved	O
lncRNA	O
uc	O
.	O
134	O
suppressed	O
the	O
progression	O
of	O
HCC	B-DS
by	O
inhibiting	O
CUL4A	B-GP
-	O
mediated	O
ubiquitination	O
of	O
LATS1	B-GP
.	O

Hippo	B-GP
kinase	I-GP
signaling	O
is	O
highly	O
conserved	O
among	O
diverse	O
species	O
and	O
regulates	O
tissue	O
overgrowth	O
and	O
development	O
[	O
51	O
].	O

The	O
classic	O
tumor	B-DS
suppressor	O
miRNA	O
let	O
-	O
7	O
is	O
also	O
conserved	O
among	O
species	O
and	O
promotes	O
cell	O
cycle	O
exit	O
and	O
cell	O
differentiation	O
both	O
during	O
normal	O
development	O
and	O
in	O
cancer	B-DS
[	O
52	O
,	O
53	O
].	O

However	O
,	O
does	O
uc	O
.	O
134	O
have	O
a	O
similar	O
developmental	O
expression	O
pattern	O
as	O
the	O
miRNA	O
let	O
-	O
7	O
?	O

It	O
will	O
be	O
interesting	O
to	O
unravel	O
the	O
underlying	O
mechanisms	O
that	O
control	O
the	O
expression	O
of	O
uc	O
.	O
134	O
in	O
both	O
cancer	B-DS
and	O
normal	O
development	O
in	O
the	O
future	O
.	O

Conclusions	O

Taken	O
together	O
,	O
our	O
data	O
indicated	O
that	O
the	O
expression	O
of	O
a	O
novel	O
lncRNA	O
,	O
uc	O
.	O
134	O
,	O
was	O
repressed	O
in	O
HCC	B-DS
specimens	O
and	O
the	O
expression	O
of	O
uc	O
.	O
134	O
was	O
significantly	O
correlated	O
with	O
the	O
overall	O
survival	O
of	O
patients	O
.	O

Notably	O
,	O
our	O
results	O
showed	O
that	O
the	O
overexpression	O
of	O
uc	O
.	O
134	O
suppressed	O
HCC	B-DS
cell	O
proliferation	O
,	O
invasion	O
,	O
and	O
metastasis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
uc	O
.	O
134	O
plays	O
a	O
crucial	O
role	O
in	O
activating	O
Hippo	B-GP
kinase	I-GP
signaling	O
by	O
inhibiting	O
CUL4A	B-GP
ubiquitination	O
of	O
LATS1	B-GP
and	O
increasing	O
YAPS127	O
phosphorylation	O
.	O

Furthermore	O
,	O
we	O
confirmed	O
that	O
uc	O
.	O
134	O
repressed	O
the	O
downstream	O
target	O
genes	O
of	O
YAP	B-GP
.	O

Finally	O
,	O
ISH	O
and	O
IHC	O
showed	O
positive	O
relationships	O
among	O
uc	O
.	O
134	O
,	O
LAST1	B-GP
,	O
and	O
pYAPS127	O
in	O
90	O
paraffin	O
-	O
embedded	O
samples	O
.	O

Consequently	O
,	O
these	O
results	O
identified	O
that	O
lncRNA	O
uc	O
.	O
134	O
activates	O
Hippo	B-GP
kinase	I-GP
signaling	O
by	O
blocking	O
CUL4A	B-GP
,	O
suggesting	O
that	O
it	O
may	O
serve	O
as	O
a	O
tumor	B-DS
suppressor	O
and	O
prognostic	O
biomarker	O
in	O
HCC	B-DS
.	O

Additional	O
files	O

Additional	O
file	O
1	O
:	O
Supplementary	O
raw	O
data	O
1	O
.	O

LncRNA	O
expression	O
profiling	O
data	O
analysis	O
by	O
lncRNA	O
microarray	O
.	O

(	O
XLS	O
2275	O
kb	O
)	O
Additional	O
file	O
2Supplementary	O
raw	O
data	O
2	O
.	O

Differentially	O
mRNA	O
expression	O
profiling	O
by	O
mRNA	O
microarray	O
.	O

(	O
XLSX	O
5963	O
kb	O
)	O
Additional	O
file	O
3	O
:	O
Supplementary	O
raw	O
data	O
3	O
.	O

The	O
full	O
GO	O
data	O
of	O
mRNA	O
microarray	O
.	O

(	O
XLS	O
336	O
kb	O
)	O
Additional	O
file	O
4	O
:	O
Oligonucleotide	O
sequences	O
and	O
primers	O
for	O
this	O
study	O
.	O

(	O
PDF	O
100	O
kb	O
)	O
Additional	O
file	O
5	O
:	O
Figure	O
S1	O
.	O
Expression	O
levels	O
of	O
six	O
lncRNAs	O
by	O
qRT	O
-	O
PCR	O
in	O
HCC	B-DS
cells	O
.	O

(	O
A	O
)	O
nc	O
-	O
HOXA11	B-GP
-	O
86	O
(	O
B	O
)	O
ENST00000426547	O
(	O
C	O
)	O
ENST00000442971	O
(	O
D	O
)	O
NR_027250	O
(	O
E	O
)	O
ENST00000400856	O
(	O
F	O
)	O
ENST00000394079	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
;	O
**	O
P	O
<	O
0	O
.	O
01	O
;	O
and	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O
Figure	O
S2	O
.	O
Full	O
-	O
length	O
of	O
human	B-OG
lncRNA	O
uc	O
.	O
134	O
gene	O
cloning	O
.	O

(	O
A	O
)	O
The	O
sequencing	O
of	O
PCR	O
products	O
from	O
the	O
5	O
′-	O
RACE	O
and	O
3	O
′-	O
RACE	O
procedures	O
showed	O
the	O
boundary	O
between	O
the	O
universal	O
anchor	O
primer	O
and	O
lncRNA	O
uc	O
.	O
134	O
sequences	O
.	O

(	O
B	O
)	O
Nucleotide	O
sequence	O
of	O
the	O
full	O
-	O
length	O
human	B-OG
lncRNA	O
uc	O
.	O
134	O
gene	O
.	O
Figure	O
S3	O
.	O
Representative	O
images	O
of	O
FISH	O
detecting	O
endogenous	O
lncRNA	O
uc	O
.	O
134	O
molecules	O
(	O
green	O
)	O
in	O
HCC	B-DS
cells	O
.	O

Nucleus	O
(	O
blue	O
)	O
was	O
stained	O
with	O
DAPI	O
.	O
Figure	O
S4	O
.	O
Transfection	O
efficiency	O
in	O
HCC	B-DS
cells	O
was	O
assessed	O
by	O
qRT	O
-	O
PCR	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
,	O
and	O
results	O
are	O
presented	O
as	O
mean	O
±	O
SD	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
and	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O
Figure	O
S5	O
.	O
Knockdown	O
of	O
uc	O
.	O
134	O
promotes	O
the	O
progression	O
and	O
invasion	O
of	O
HCC	B-DS
in	O
vitro	O
and	O
in	O
vivo	O
.	O

(	O
A	O
)	O
Growth	O
curves	O
of	O
HCC	B-DS
cells	O
generated	O
by	O
CCK8	O
proliferation	O
analysis	O
.	O

The	O
mean	O
±	O
SD	O
is	O
shown	O
for	O
five	O
independent	O
experiments	O
.	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O

(	O
B	O
)	O
The	O
colony	O
formation	O
assays	O
(	O
left	O
panels	O
);	O
analysis	O
of	O
the	O
number	O
of	O
colonies	O
(	O
right	O
panels	O
).	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
,	O
and	O
results	O
are	O
presented	O
as	O
mean	O
±	O
SD	O
.	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O

(	O
C	O
)	O
Transwell	O
assay	O
for	O
the	O
indicated	O
cells	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
,	O
and	O
results	O
are	O
presented	O
as	O
mean	O
±	O
SD	O
.	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O

(	O
D	O
)	O
Representative	O
images	O
of	O
the	O
scratch	O
wound	O
-	O
healing	O
assay	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
,	O
and	O
results	O
are	O
presented	O
as	O
mean	O
±	O
SD	O
.	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O

(	O
E	O
)	O
Tumors	B-DS
formed	O
by	O
cells	O
transfected	O
with	O
EGFP	B-GP
-	O
LV	O
-	O
shRNA	O
targeting	O
uc	O
.	O
134	O
were	O
markedly	O
larger	O
and	O
grew	O
faster	O
than	O
tumors	B-DS
formed	O
by	O
control	O
cells	O
.	O

(	O
n	O
=	O
5	O
)	O
*	O
P	O
<	O
0	O
.	O
05	O
.	O

(	O
F	O
)	O
Lung	O
metastasis	O
model	O
generated	O
by	O
injecting	O
cancer	B-DS
cells	O
into	O
the	O
tail	O
veins	O
of	O
mice	B-OG
.	O

HE	O
staining	O
shows	O
the	O
number	O
and	O
volume	O
of	O
lung	O
metastases	O
in	O
each	O
group	O
(	O
n	O
=	O
6	O
)	O
**	O
P	O
<	O
0	O
.	O
01	O
.	O
Figure	O
S6	O
.	O
The	O
histologic	O
examination	O
of	O
tumors	B-DS
.	O

Upper	O
panels	O
:	O
ISH	O
staining	O
,	O
middle	O
panels	O
:	O
KI67	B-GP
staining	O
,	O
lower	O
panels	O
:	O
HE	O
staining	O
.	O
Figure	O
S7	O
.	O
LATS1	B-GP
and	O
pYAPS127	O
expression	O
levels	O
in	O
HCC	B-DS
specimens	O
.	O

(	O
A	O
,	O
B	O
)	O
IHC	O
analysis	O
in	O
90	O
primary	O
clinical	O
specimens	O
showed	O
that	O
the	O
expression	O
levels	O
of	O
LATS1	B-GP
and	O
pYAPS127	O
were	O
significantly	O
depressed	O
in	O
tumors	B-DS
compared	O
with	O
adjacent	O
tissues	O
.	O

(	O
C	O
,	O
D	O
)	O
Lower	O
expression	O
levels	O
of	O
LATS1	B-GP
and	O
pYAPS127	O
were	O
related	O
to	O
the	O
poor	O
survival	O
of	O
patients	O
.	O

(	O
PDF	O
5721	O
kb	O
)	O

